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Vaccine production is one of the most important applications of biotechnology. Virus-
like particles (VLP) serve well the purpose of a safe and effective vaccine. Yet till now 
many aspects of this biological tool have been under discovered. In present work, an 
effort has been made to characterize the structural aspects of genetically modified 
VLPs. As a model system, hepatitis B surface antigen (HBsAg) VLPs have been 
produced in methylotrophic yeast, Pichia pastoris. In the initial part of the work, 
downstream processing has been probed to discover the crucial points in gradual 
development of VLP formation. In later part, the purified VLPs have been subjected to 
chaotropic conditions to observe the type and extent of molecular forces holding these 
tiny particles together.  
Self-assembly, from subunits to a well defined symmetry, is the most prominent 
characteristic of VLPs, however, little is known about when and how they appear in 
the process. It has been observed in previous studies that no VLPs are observed during 
the cultivation in Pichia pastoris cells. In order to pinpoint the most crucial steps for 
VLP assembly, samples were collected during the downstream process. Transmission 
electron microscopy was used to examine samples from multi-step purification and the 
data was analyzed to draw a quantitative relation. During initial steps of the 
purification process, no VLPs were observed despite the presence of enough amount of 
HBsAg protein. Adequate VLP count was observed only after adsorption on the 
hydrophobic resin. Control experiments using non-HBsAg-producing Pichia pastoris 
cells were carried out to observe the background structures and their influence. These 
control experiments, containing VLPs, in presence and absence of suspected agents 
clearly prove that host cell components as well as buffer system are decisive factors in 
the in vitro assembly process of HBsAg. 
The stability tests were performed in the presence of denaturants and changes in VLP 
structure and size were ascertained via fluorescence spectroscopy (intrinsic and 
extrinsic) and dynamic light scattering (DLS). The trend in structural changes as a 
function of molarity of the salts indicates that VLPs undergo denaturation process by 
several intermediates, which may occur as a cascade of reactions involving gradual 
detachment of subunits. 
Key words: Hepatitis B surface antigen, Virus-like particle, Self-assembly, 
Transmission electron microscopy, Steady-state fluorescence spectroscopy, Dynamic 





Die Herstellung von Vakzinen ist eine der wichtigsten Anwendungen in der 
Biotechnologie. Virusartige Partikel (VLPs) werden als ungefährliche und effektive 
Impfstoffe eingesetzt. Dennoch sind viele Aspekte dieser  biologischen Werkzeuge bis 
heute immer noch nicht genügend erforscht. In dieser Arbeit werden die strukturellen 
Aspekte von genetisch veränderten VLPs charakterisiert. Als ein Modellsystem diente 
Hepatitis B Oberflächenantigen (HBsAg) Protein, das in der methylotrophen Hefe, 
Pichia pastoris, produziert wurde. Im ersten Teil dieser Arbeit wurde der 
Aufreinigungsprozess untersucht, um die entscheidenden Schritte während der 
allmählichen Entwicklung der VLP Bildung zu erforschen. Im späteren Teil dieser 
Arbeit wurden die aufgereinigten VLPs unter chaotropen Bedingungen untersucht, um 
die Art und das Ausmaß der molekularen Kräfte, die diese Partikel zusammenhalten, 
zu analysieren. 
Selbstassemblierung von Monomeren zu gut definierter Symmetrie ist die bekannteste 
Eigenschaft der VLPs, aber es ist wenig bekannt darüber, wie und wann die VLPs 
während der Aufreinigung gebildet werden. Es wurde in den letzten Studien 
beobachtet, dass keine VLPs in Pichia pastoris Zellen während der Kultivierung 
auftreten. Um den wichtigsten Punkt der Selbstassemblierung der VLPs genau 
bestimmen zu können, wurden Proben während der Aufreinigung entnommen. 
Mithilfe der Transmissionselektronenmikroskopie wurden die Proben der mehrstufigen 
Aufreinigung charakterisiert und die ermittelten Daten zur Quantifizierung der VLP 
Bildung eingesetzt. Während der Anfangsschritte der Aufreinigung wurden keine 
VLPs trotz der Anwesenheit von genügend HBsAg gefunden. Eine ausreichende 
Anzahl an VLPs wurde jedoch nach dem Aufreinigungsschritt mittels hydrophobem 
Harz festgestellt. Es wurden Kontrollversuche mit nicht produzierenden HBsAg Pichia 
pastoris Zellen durchgeführt, um die Strukturen des Hintergrunds und deren Einfluss 
auf die VLP Bildung zu beobachten. Diese Kontrollproben, die VLPs enthalten, zeigen 
in An- und Abwesenheit der vermuteten Wirkstoffe deutlich, dass die 
Wirtszellkomponenten sowie das Puffersystem entscheidende Faktoren für den in vitro 
Selbstassemblierungs-prozess des HBsAgs darstellen. 
Die Stabilitätstests wurden in Anwesenheit von Denaturierungsmitteln durchgeführt 
und die Veränderungen der VLP-struktur und -Größe mithilfe der Fluoreszenz-




nachgewiesen. Der Trend der strukturellen Veränderungen als Funktion der Molarität 
der Denaturierungsmittel zeigt, dass VLPs einen Denaturierungsprozess mit vielen 
Zwischenprodukten durchlaufen, der eine Art Kaskadenreaktion mit schrittweiser 
Abtrennung von Monomeren darstellt.  
Stichwörter: Hepatitis B Oberflächenantigen, Virusähnliche Partikel, Selbst-
assemblierung, Transmissionselektronenmikroskopie, Steady-state Fluoreszenz-







1. Theoretical background 
Hepatitis B is a viral infection that attacks the liver and can cause both acute and 
chronic disease. According to the WHO (World Health Organization), an estimated 
two billion people, about one third of the world’s population, have been infected with 
the hepatitis B virus (HBV), and more than 350 million have chronic (long-term) liver 
infections [1]. HBV belongs to the hepadnaviridae family and has a DNA genome 
(3.2 kb) that is replicated via an RNA intermediate. Depending on the patient’s 
immune response, infection by HBV can be asymptomatic, chronic or acute [2]. In 
acute illness, the infection lasts for 2-3 weeks and patient’s liver needs about 6 months 
to recover completely. In chronic hepatitis B, the infection leads to chronic liver 
inflammation including liver cirrhosis and ultimately hepatocellular carcinoma. 
 
Figure 1.1. Geographic prevalence of chronic infection with hepatitis virus surveyed until 






1.1. Epidemiology of HBV 
The environmental factors such as healthy life style and safe health care system play 
the major role to prevent the spread of disease. The common means of spreading HBV 
are through sexual contact with infected person, percutaneous or mucosal exposure to 
infectious blood and vertical (perinatal) transmission [4]. Despite the fact that there 
exists a vaccine against hepatitis B since 1980s, its incidence has been increasing. Due 
to recommendations by WHO, the prevalence of disease has been decreased in several 
countries e.g., in Korea, where more than 98.9% infants have been vaccinated since 
1990, the prevalence of HBV carriage has declined greatly [5]. Similarly in Europe, 
the reported HBV cases per 100,000 have declined from 6.7 to 1.5 during 1995-2007 
[6]. However weak immunization strategies in other countries and limited domestic 
funding in many more create challenges to achieving regional targets. 
The major endemic regions facing the problem of hepatitis B are China and central and 
southern parts of Africa [7]. The disease is relatively rare in western countries and is 
usually observed in adults. On the other hand, in Asia and Africa, hepatitis B is 
acquired during the childhood, mostly via perinatal transmission [7]. Apart from 
endemic regions, southern parts of east and central Europe, the Middle East, the 
Amazon and the Indian subcontinent show quite high occurrence of hepatitis B. Most 
of the cancer cases, not only in parts of Africa and Asia but also in developed 
countries, are due to primary liver cancer caused by hepatitis B [8, 9]. 
WHO has recommended that each child should get their vaccine dose against hepatitis 
B as soon as possible, preferably within 24 hours after the birth. The first dosage is 
followed by 2 or 3 more doses depending on the pattern adopted for vaccination. Two 
further doses are enough if they are given simultaneously with first and third dose of 
DPT vaccine (diphtheria-pertussis-tetanus vaccine). The younger cohorts should be 
given priority for catch-up vaccination as they face a higher risk of chronic illness. 
Additionally, people who are under medical treatment where they require blood-related 
therapy or other blood exchange activity, face a high risk and therefore should be given 
a booster dose [10]. In more than 90 % of the adult patients, the infection clears 





1.2. HBV genomic organization 
The hepatitis B virus has a partially double stranded circular DNA of approximately 
3200 base pairs. HBV has four overlapping open reading frames (ORFs) which encode 
seven polypeptides [12]. The seven polypeptides constitute the surface- and coat-
proteins, transcriptional transactivator, polymerase, reverse transcriptase and RNase. 
The envelope protein genes i.e., pre-S1 (large), pre-S2 (middle), and S (small or 
surface) overlap with the polymerase ORF [13]. 
 
Figure 1.2. The physical map of hepatitis B genomic organization [13]. 
The viral polymerase is covalently attached to the 5’ end of the minus strand which is 
the longest and contains an ORF that encodes for viral proteins and the cis-elements 
responsible for regulation of HBV gene expression and replication. A plus strand of 
variable length maintains the circular structure of the cohesive hybridization that 
straddles the 5’ and 3’ ends of the minus strand [14]. 
1.3. Hepatitis B virus morphology 
The hepatitis B virus has an icosahedral shape with an outer coat. Electron microscopy 





spherical one with 22 nm diameter. The second most common is the filamentous or 
tubular form also with 22 nm diameter but in length may reach up to 200 nm. These 
both forms are devoid of DNA. The third and least observed form is the 42 nm 
spherical virus, originally referred to as Dane particle. 
 
Figure 1.3. Illustration of a HBV-particle, also known as the Dane particle. The outer 
surface (coat) of the virus consists of three types of HBV surface antigens. In addition to 
the icosahedral core, made up of core protein (HBc), the virus contains viral DNA and the 
polymerase enzyme inside the inner core. With permission, adapted from © 2002 James 
A. Perkins, Medical and Scientific illustrations. 
Structurally, HBV consists of three major components, surface proteins, core proteins 
and the genetic material (Figure 1.3). The surface coat itself comprises three proteins 
i.e., large protein (L-protein), medium protein (M-protein) and small protein (S-
protein). There have been continuous efforts since decades to develop a recombinant 
vaccine against hepatitis B inspired by different immunogenic domains of the original 
virus, for example, VLP vaccines made up of only core protein. [15]. Out of all three 
components, the most attractive and popular candidate, with respect to efficacy, is the 
surface antigen, known as hepatitis B surface antigen (HBsAg). 
Small surface protein (S)
Core protein (HBc)
Medium surface protein 
(S + PreS2)
Large surface protein









Figure 1.4. A schematic representation of surface proteins of HBV. The S-region is 
common in all of the surface antigens, which comprises 226 amino acids.  
All of the envelope proteins contain the sequence of the small protein i.e. S-region, 
whereas the two other proteins have additional amino acid sequence namely preS1 and 
preS2 (Figure 1.4). All three domains contain regions which are targets for neutralizing 
antibodies. The preS1 region directly binds to the cellular receptor whereas the preS2 
sequence binds to the albumin receptor. The small protein is not directly involved in 
binding to the liver cell membrane, however, antibodies against this protein have a 
good neutralizing effect [16]. 
1.4. Mechanism of virus-mediated immune response  
In general pathogens are averted from entering the human body in the first place via 
innate immunity which comprises of first and (partially) second line of defense. First 
line of defense of the immune system consists of various physical (e.g., skin) and 
chemical barriers (mucous, saliva, vaginal fluid etc) to prevent the virus from entering 
the body. Still if the virus manages to enter inside the human body, it has to deal with 
immune system at further levels [17]. When HBV enters the body via body fluids, it 
passes through blood and here the second line of defense comes in action. This is 
characterized by production of type 1 interferon (IFN)-α/β cytokines and the activation 
of natural killer (NK) cells [18, 19]. If HBV is able to pass through the innate immune 
system, it enters the hepatic cells where it undergoes multiple cycles of replication and 
the shredding occurs into the blood [20].   
Depending on the stage of infection, various markers can be observed in the blood. 
Four major serological markers are i. hepatitis B surface antigen, ii. hepatitis B surface 
antibody (anti-HBs), iii. total hepatitis B core antibody (anti-HBc) and iv. IgM 
antibody to hepatitis B core antigen (IgM anti-HBc). HBsAg is one of the initial 
markers appearing in third week after exposure and persists by the sixth month. From 
HBsAg gene
PreS1            PreS2     S protein
1                    119          174                                 400
LHBs
1                    119          174                                 400
MHBs
119          174                                 400
SHBs





second month of infection, high levels of IgM anti-HBc are detectable. Anti-HBs is 
observed variably from sixth month, after the disappearance of HBsAg [2]. 
By definition, hepatitis is inflammation of the liver but none of the hepatitis-inducing 
viruses, including HBV, are typically cytopathogenic. The HBV DNA integrates into 
host genome and the cellular damage observed in hepatitis is supposedly a result of 
immune response against infected hepatocytes [20]. 
1.5. HBV replication cycle 
The life cycle of the HBV inside the human body is similar as that of other viral 
cycles. After entering, first the capsid gets attached to the hepatocytic surface via 
specific receptors [21] and double stranded DNA is released inside the hepatocyte [22]. 
Within the host nucleus, this viral DNA is converted into cccDNA (covalently closed 
circular DNA) which replicates to create several transcript copies including pregenome 
RNA [23]. 
 
Figure 1.5. HBV replication cycle: HBV gets attached to a receptor on the surface of the 
cell. The capsid enters the cell, cccDNA replicates inside the host nucleus to produce 
several copies of pregenome RNA which is encapsidated and continues the cycle either in 



























Pregenome RNA is encapsidated with core protein and single-strand DNA is 
synthesized by viral polymerase within the core. Core particles bud from pre-Golgi 
compartment, acquire surface protein and exit the hepatocyte or enter another cycle of 
intracellular replication [23].  
1.6. Vaccines for hepatitis B 
The vaccines against hepatitis B exist since a while but the death toll caused by it is 
still increasing. Among many other reasons, it is because of absence of a suitable-for-
all vaccine. In general, about 1-10% of healthy adults show non-response to vaccine 
because of one or the other reason. Therefore there is still a dire need of hepatitis B 
vaccine candidates with better immunogenic response and simpler delivery system. 
HBsAg, originally know as Australia antigen, was first discovered by Blumberg et al. 
in 1965 in sera of leukemia patients [25]. Soon it was adapted to be exploited as 
vaccine against hepatitis B. Presently, various types of vaccines against hepatitis B are 
available. 
1.6.1. Plasma-derived vaccines 
The early efforts to propagate HBV in cell cultures were unsuccessful therefore it has 
not been fruitful to develop vaccine based on virus expressed in cell cultures [26, 27]. 
When infected with HBV, cell cultures produce low yield due to poor viral replication 
[28]. Other option was isolation of HBV particles (22 nm) from plasma of 
asymptomatic human carriers. The first generation of hepatitis B vaccine was 
developed from the formalin- or heat-inactivated virions from plasma of carrier 
patients [29].  
The first plasma-derived vaccines were licensed in USA and France in 1981-1982. In 
addition to inadequacy of plasma, there have been many safety issues associated with 
plasma-derived vaccine. The risk of presence of active virus or viral DNA makes them 
unfavorite as a vaccine candidate. Occurrence of some undetected infectious agents in 
vaccine, despite the careful procedure of isolation from human plasma, has been a 
matter of concern [30]. Although plasma-derived vaccines are no longer produced in 






1.6.2. DNA vaccines 
The naked DNA can be injected as expression plasmid which is taken up by the cells. 
This results in the expression of respective antigen which triggers the immune 
response [31]. In case of hepatitis B, this approach has been applied so far in mice 
using pDNA encoding HBsAg and has been reported to produce significant humoral 
and cellular response [32].  
In general, in plasma- and DNA-derived vaccines, the results are less promising due to 
their tendency to contamination. Particularly in developing countries, where there is 
always a risk of contamination because of backward health care system, plasma 
derived vaccines are less successful. 
1.6.3. Subunits vaccines 
Subunit vaccines, as the name suggests, are the vaccines based on antigenic domains of 
the viral coat. In case of hepatitis B, polypeptide subunits have been tested in non-
human primates and clinical tests have been carried out [29]. A trial of synthetic 
peptide vaccine comprising 19 amino acid residues from the pre-S2 protein (residues 
14-32 from the N terminus) has been proven successful to produce immunological 
efficacy in chimpanzees [33]. The subunit has been stated to be expressed in E. coli in 
a number of reports [34, 35].  
1.6.4. VLP-based vaccines 
The HBsAg VLP-based vaccine has been one of the most significant success stories in 
biotechnology. The vaccine in common use today was approved in 1986 by US FDA 
and is considered as world's first genetically engineered vaccine [36]. It is also 
considered as the first vaccine against any cancer i.e. hepatocellular carcinoma. This 
vaccine comprises small virus-like particles (VLPs) which resemble the virus actually 
causing the disease with the major difference being that they lake genetic material i.e., 
they are non-infectious.  
During infection, two types of viral particles are frequently produced. The infectious 
types, Dane particles, are about 44 nm in size. During chronic infection, HBsAg is 
expressed also as another non-infectious quasi-spherical from, with 22 nm of size. 





1.7. Expression systems used for HBV vaccine production 
The most common antigen used against hepatitis B as vaccine is the surface antigen. 
HBsAg has been successfully synthesized in a number of microbial systems. Like any 
other biopharmaceutical product, each system offers its advantages and disadvantages. 
In case of E. coli, the expression of HBsAg polypeptide was successful but the activity 
could not be verified by radioimmunoassay [38]. The VLP formation ability has been 
very poor either because of lack of glycosylation of HBsAg derivatives [35] or because 
of inefficient transcription [34]; although the HBV genome does not contain ‘introns’ 
which E. coli is believed to be unable of transcribing [39]. 
Subsequently, Saccharomyces cerevisiae was employed as an alternative host system 
for the expression of HBsAg. The first successful commercial vaccine invented against 
hepatitis B virus (HBV) in 1984 was expressed in S. cerevisiae [40-42]. Till now, only 
two FDA approved vaccines, Engerix-B® (GlaxoSmithKline) and Recombivax HB® 
(Merck and Co. Inc.), are produced in S. cerevisiae. 
Apart from S. cerevisiae, HBsAg has been expressed in other fungal systems such as 
Pichia pastoris, Hansenula polymorpha [43] and Aspergillus niger [44]. Commercially 
available H. polymorpha-derived vaccines are Hepavax-Gene (KGCC, Korea) and 
AgB (LPC, Argentina) [45]. In general, A. niger serves many inherent advantages such 
as glycosylation more similar to that of in humans and higher product yield but the 
cultivation process is rather tricky due to the danger of spore dust formation [46]. 
HBV antigens have been reported to be expressed also in viral expression systems. 
Both surface and core antigens were co-expressed in Vaccinia virus which resulted in 
formation of either HBsAg or HBcAg viral particles [47]. Further alternatives include 
adenovirus and baculovirus expression system. 
Other successful expression systems in trial comprise Plant cell cultures [48-50], 






1.8. Pichia pastoris as expression host 
As mentioned earlier, initially there have been efforts to express HBsAg in E. coli but 
there had been problems with the retention of the plasmid. Also, the immunogenic 
response was relatively less effective as compared to that generated by yeast-derived 
HBsAg [38, 54]. The isolation of a yeast specie capable of methanol assimilation as 
sole source of carbon and energy was reported for the first time in 1969 [55].  
Pichia pastoris has been an attractive host system for the heterologous protein 
production due to many evident reasons. It is possible to produce large amount of 
recombinant protein by inserting multiple copies of target genes. P. pastoris has a 
strong, inducible promoter that can be used for protein production [56]. By and large 
the yields are good, final cell density of cultivation is high and post-translational 
modifications are correctly oriented [57-59]. In general, it is practicable to obtain the 
protein in active form in the medium. It is easy to grow to high cell density and being a 
eukaryote, P. pastoris is able to carry out the post-translational modifications. 
Certainly, there are also some bottlenecks for P. pastoris as expression host system, 
especially with higher gene dosage. It is well known that expression can be increased 
significantly by increasing the gene dosage [60, 61] although in case of certain 
proteins, this may cause cellular stress [62]. The burden due to increased gene dosage 
causes protein folding stress which can lead to product accumulation in the ER [63].  
1.9. VLPs as vaccines 
VLPs are the nonreplicating virus capsids made by using recombinant DNA 
technology that mimic the structure of native virions. They are effective inducers of 
neutralizing antibodies as well as T-cell response. VLPs contain typically viral 
structural units, capsid or envelope, with absence of some elements required for 
assembly and viral genome and still capable of triggering immunologic effect. 
According to a view, the assembly pathway is difficult to establish because the 
polymerization is rapid and it is not always a single high-order reaction [64]. Usually 
VLP derived vaccines consist of one or more antigenic regions of original virus, which 
are allowed to self-assemble. Recombinant hepatitis B surface antigen (HBsAg) 





immunogenic effect of native virus. One subunit of HBsAg is 25 kDa and consists of 
226 amino acids.  
 
Figure 1.6. A cartoon of HBV (left) in comparison with HBsAg VLP right). Three 
surface antigens are large surface protein (LHBs), middle surface protein (MHBs) and 
small surface protein (SHBs). HBV core is made up of core protein (HBc). In addition to 
that, HBV contains reverse transcriptase (RT), RNA primer (Pri) and protein kinase (PK). 
The small surface antigen gene is expressed heterologously and has the property to self-
assemble into VLPs (right). 
VLP vaccines offer many lucrative advantages over the parallel alternatives. Their 
prime advantage is the absence of genetic material which promises absence of 
mutations and infection. Many deleterious effects of attenuated vaccine can be avoided 
by adapting the VLP approach. In general, the immunogenic stimulus is strong which 
triggers both humoral and cellular responses. Depending on the expression system, the 
production costs can be cut to many folds low as compared to the conventional 
(attenuated and inactivated) vaccines. In case of microbial expression systems, large 
production scale and good yields guarantee the high profitability. 
VLPs formed by the structural elements of viruses have received considerable attention 
over the past two decades and are considered as potential approach for future. Apart 
from hepatitis B, this technology can be proven useful in preparation of vaccines 
against many other viruses such as Dengue virus [65], Human papilloma virus (HPV) 
















30 VLP based vaccine for humans and other animals have been developed till date 
[68]. 
1.10. Immunogenic properties of VLPs 
In general, VLPs are more immunogenic as compared to the corresponding single 
subunits [69]. VLPs have potency to stimulate both cellular and humoral arms of the 
immune system. The repeated and ordered organization of subunits link with the 
specific immunoglobulins (Igs) which makes VLP ideal for triggering B-cell response 
[70]. 
 
Figure 1.7. Supposed mechanism of Immunogenic interaction of a VLP inside the body; 
adapted from Ludwig et al. [71] (reproduced with permission). 
Due to their relatively smaller size, it is easy for dendritic cells to uptake VLPs. The 
mechanism of VLP-mediated immune response involves the uptake of VLPs by 
dendritic cells (DCs) which result in the appearance of signals on the surface of these 
cells (Figure 1.7). These DCs are later transported to the lymphatic nodes to be 





1.11. VLP assembly 
Despite the availability of HBsAg vaccine since 25 years, its structure at molecular 
level and the mechanism of self-assembly of the VLPs is not fully known.  There have 
been some efforts to understand this mechanism in real viruses but in the field of 
VLPs, this area is still under-explored. The mechanism by which HBsAg undergoes 
VLP formation is of special interest as it may open prospects to other VLP based 
vaccines. As far as the mechanism of VLP formation in mammalian cells is concerned, 
it is relatively straightforward. For example in case of human hepatocytes, the particles 
are formed in ER (endoplasmic reticulum). They are retained in the ER lumen for 
some time and later excreted out to the intercellular space [72, 73]. 
In simpler expression systems, the process of secretion of HBsAg VLPs is rather 
tricky. In CHO cells, electron micrographs show the HBsAg accumulation in dilated 
areas of ER. Here the HBsAg resides in form of collection of filamentous structures 
with half time for secretion of about 5 h [74]. No HBsAg particles could be observed 
in the plant cell culture. Their failure to progress further than ER (or the Golgi) has 
been described as a result of presence of the cell wall [48]. In case of yeast, it has 
already been described that the assembly does not take place in vivo during the 
expression, [75] which leads to the conclusion that this process occurs during the 
downstream process.  
Apart from protein physical properties, other decisive factors involved are environment 
components of protein solution. Physiochemical conditions like pH, ionic strength and 
temperature play important role in correct assembly process [76]. Moreover, the 
influence of stoichiometric ratio of structural (subunit) proteins on the concentration of 
assembled particles has been intensively studied [77].  
It was considered in the past that there are no intermediates present in the HBsAg 
assembly process [78] however recently it has been reported that intermediates were 
trapped by phenylpropenamide assembly accelerators [79]. Theoretically, a capsid can 
undergo assembly via exponential folds of intermediates. For hepatitis B capsid, taking 
into account 120 dimers, a least magnitude of the order of 10
26
 is possible, where as for 







1.12. Physicochemical features of HBsAg 
HBsAg subunits are the building blocks of hepatitis B VLP, with one subunit being 
25 kDa in size. About 100 subunits, along with host cell lipids, assemble together to 
constitute one VLP. To understand the assembly mechanism, one needs to understand 
the structural aspects of single subunit protein. HBsAg is a hydrophobic protein which 
consists of mostly hydrophobic amino acids, as it is obvious from its hydopathy plot 
(Figure 1.8). 
 
Figure 1.8. Kyte and Doolittle plot of the HBsAg amino acid sequence. The X-axis plots 
the 226 amino acids of the protein, whereas the Y-axis plots the respective hydropathy 
scale (http://web.expasy.org/protscale/). 
Chemically, HBsAg VLPs are composed of protein and lipid contents in a ratio of 
60:40 respectively [52, 81]. Unlike typical (membrane) lipoproteins, HBsAg VLPs 
exhibit peculiar spatial arrangement of lipids. Instead of a lipid bilayer arranged around 
the protein layer, HBsAg particles have lipid layer embedded towards the inner region 
constituting hydrophobic core whereas the hydrophilic protein part faces towards the 
outside [82]. The lipids help to maintain the native conformation [83] and hence have 
an important influence on the immunogenic prosperities. This is evident from 
dissimilarity in immunogenic properties of HBsAg particles obtained from different 
sources. It is observed that when the same HBsAg encoded by the same DNA 



















sequence is expressed in different heterologous systems, exhibit different immunologic 
behavior [84].  
In addition to lipids, plasma-derived HBsAg is reported to contain carbohydrate 
moiety. Peterson et al. have been suggested that the amino acid region 122-150 of the 
subunit protein (named as p-25) and its glycosylated form (named as gp-30) in HBsAg 
particle, isolated from the plasma of chronic carrier, exhibits an attachment site for 
carbohydrates [85]. Both proteins, p-25 and gp-30, contain 226 amino acids. 
The antigenicity of HBsAg particles is dependent upon the correct disulfide bonds 
among the amino acids present in region aa101-172, the so-called a-determinant [86]. 
Several immunologic assays exploit this property to detect the presence of antigen in 
the serum [87]. The correct disulfide bonding in HBsAg dimers facilitates the correct 
conformation required for the in vitro VLP formation (Figure 1.9-B). 
The cryomicroscopic studies of truncated form of HBV core protein (aa 1-149) suggest 
hydrophobic domains and disulfide bond between the monomers, as shown in figure 
1.9 [88]. 
 
Figure 1.9. Structure of HBV capsid monomer: (A): The lower region of protein with 
aromatic amino acid residues (highlighted in red) constitutes the hydrophobic core. (B): 
HBsAg dimeric form. The disulfide bond between two monomers (shown in green) arises 
from Cys-61. With permission, reprinted from Wynne et al. [88]. 
CD spectroscopy shows that α-helix is the most abundant secondary structure found in 
HBsAg, constituting about 50% of the total protein structure. Some of these α-helices 







2. Objectives of the thesis 
Virus-like particles (VLPs) as vaccines have proven to be a promising option against 
several diseases. However despite of being an important mean to prevent millions of 
casualties worldwide, there has been an imperative need to investigate the process of 
self-assembly from protein subunits into the VLPs. In this thesis, HBsAg was taken as 
a model system to study the in vitro assembly process of VLPs. HBsAg VLP-based 
vaccine has been one of the most important success stories in biotechnology [36]. It is 
considered as the first vaccine against a cancer i.e., hepatocellular carcinoma.  
Insight into the assembly process is important because (a) It will facilitate to develop 
new vaccines based on VLP technology, (b) It will be convenient to administer product 
homogeneity and quality, and (c) It will help to produce the VLPs with better 
immunogenicity. Moreover, in vitro investigation provides the possibility to 
manipulate the original process, e.g., disassembly and reassembly, leading to the 
resulting product which is more stable and effective. 
It is known that the VLPs are not present intracellularly during HBsAg production in 
the yeast cells [75]. Therefore it was concluded that the assembly process takes place 
in vitro during the downstream process. Until now, there has not been any report about 
the monitoring of assembly process in HBsAg during downstream processing, which 
brings it to the aims of this thesis. The explicit purpose of this thesis was to answer the 
following questions: 
How to obtain high quality HBsAg VLPs during downstream process? 
How to probe the downstream process to monitor the VLP production? 
How to provide better insight into assembly process using electron microscopic study? 
How stable is the VLP structure and what happens when it is defolded? 
The primary objective of this study is to apprehend the key aspects of in vitro VLP 
assembly. This report mainly focuses on the factors affecting the self-assembly of 
HBsAg VLPs during the downstream process. The suggested factors influencing the 
assembly being stated here are main constituents of the microenvironment such as host 





these factors together and individually with respect to their influence on VLPs. Several 
control experiments have been carried out to investigate the effect of above stated 
factors, together as well as individually. 
The second aim of this work is to better understand the stability and structural aspects 
of VLPs and the changes induced therein by the addition of denaturing agents. The 
purified VLPs have been subjected to defolding process by addition of chaotropic 
salts. These changes have been observed via analytical tools like fluorescence 
spectroscopy and dynamic light scattering technique. Based on these observations, 








3. Experimental methods 
In this chapter, procedures of the major experiments performed will be stated. Their 
outcome will be discussed in the coming chapter, section-wise.  
3.1. Strain and vector for HBsAg expression 
The Pichia pastoris host strain used in this study to generate the HBsAg expressing 
transformants has been described previously [90]. Briefly, it is GS115 (HIS4), a 
histidine requiring auxotroph strain. The parent plasmid is pAO815 which contains the 
AOX1 promoter with 8-copy HBsAg expression cassette inserted in it. The HBsAg 
producing strain was initially classified as Mut
S
 phenotype [90] but in a recent study in 
our group, the presence of AOX1 gene has been reported, referring it to as a Mut
+
 
phenotype [91]. It has been proposed earlier that expression of HBsAg makes the 
strain relatively slow as it takes more time to grow biomass and to express the 
recombinant protein, but this slower growth rate is considered to improve the 
percentage of HBsAg polypeptides which are later assembled into VLPs [92]. 
3.2. Preliminary expression of HBsAg in Pichia pastoris  
To test the HBsAg expression, shake flask cultures of P. pastoris harboring HBsAg 
gene as well as P. pastoris GS115 (wild type) were grown and different media were 
used in growth of the cultures before and after induction under different conditions. 
The recipes of these media are given in the Appendix. For preliminary shake flask 
tests, the temperature and agitation were kept constant at 30°C and 250 rpm 
respectively. All the cultivations were done at least in duplicate. Initially, the 
expression of HBsAg was analyzed by SDS-PAGE.  
A- Buffered Media 
Different kinds of buffered media were chosen with minimal and complex 
composition. One of the media used was BMG (Buffered Minimal Glycerol) which is 
composed of 100 mM potassium phosphate, pH 6.0; 1.34% (w/v) yeast nitrogen base 
(YNB); 4 x 10
-5





cultivations, BMM (Buffered Minimal Methanol) was used which has the same 
composition with exception of 0.5% methanol instead of 1% glycerol.  
Another parallel expression was performed using BMGY (Buffered Glycerol-complex 
Medium), which included 1% (w/v) yeast extract and 2% (w/v) peptone in addition to 
100 mM potassium phosphate, pH 6.0, 1.34% (w/v) YNB, 4 x 10
-5
% (w/v) biotin and 
1% (v/v) glycerol. As the biomass reached to the desired OD, the cells were introduced 
with BMMY (Buffered Methanol-complex Medium) which has same composition as 
that of BMGY except having 0.5% (v/v) methanol instead of 1% (v/v) glycerol. 
Media BMG and BMGY were used to raise a biomass followed by media BMGY and 
BMMY induced with regular addition of MeOH i.e., 0.5% volume after every 24 
hours, according to manufacturer’s instructions [Pichia expression Kit, Catalog no. 
K1710-01, Invitrogen USA]. 
B- Defined Media  
Defined medium A (DM A) has composition per liter as follows; 95.2 g (as well as 
60 g, as DM-B) glycerol, 15.7 g (NH4)2SO4, 9.4 g KH2PO4, 1.83 g MgSO4.7H2O, 0.28 
g CaCl2.2H2O, 0.4 mg biotin and 1.14 g yeast trace metal (YTM) solution.  
The YTM solution (1 L) contains 760.6 mg MnSO4.H2O, 484 mg Na2MoO4, 46.3 mg 
H3BO3, 5.032 g ZnSO4.7H2O, 12.0 g FeCl3.6H2O, 207.5 mg KI and 9.2 g H2SO4.  
C- Semi Defined Media 
The semi-defined media used include casein 1% to total volume as the complex 
ingredient. Semi-defined medium (Semi-DM) comprises of (per liter) 60 g Glycerol, 
10 g Casein hydrolysate, 9 g (NH4)2SO4, 4.3 g KH2PO4, 3.2 g MgSO4.7H2O, 0.22 g 
CaCl2.2H2O and 5 mL Pichia trace metal solution (PTM1) solution. 
The recipe of PTM1 is 6.0 g/L CuSO4.5H2O, 0.08 g/L NaI, 3.0 g/L MnSO4.H2O, 
0.2 g/L Na2MoO4.2H2O, 0.02 g/L H3BO3, 0.5 g/L CoCl2 (/CoCl3), 20.0 g/L ZnCl2, 
65.0 g/l FeSO4.7H2O, 5.0 ml H2SO4 and 0.2 g/L biotin [Pichia fermentation process 





All the media were sterilized by autoclaving at 121˚C for 20 min. The fine 
components, for example biotin and YTM solution, were filter sterilized. In all the 
initial shake flask cultivations, 100 µL of glycerol stock solution which contained ≈2.6 
x 10
9 
cell/mL (OD600 = 52) was introduced to 50 mL media. Subsequently, cells were 
grown in shake flasks at one liter scale to monitor the production yield of the strain and 
the medium. 
3.3. High cell density cultivation of P. pastoris GS115 Mut+ 
As a next step, cultivation was upscaled to bioreactor level. To start the pre-inoculum, 
100 µL of the HBsAg producing P. pastoris glycerol stock was introduced in 100 mL 
of BMGY (buffered media with glycerol) and incubated for 12-16 h until the OD600 
reached 15. 10 mL of this pre-inoculum was introduced in 1 L BMGY to start the 
inoculum, which was incubated until OD600 = 8. After almost 14 h, the inoculum (1 L) 
was added in 9 L simple defined media to start the main culture [93]. 
The cultivation was carried out in a 10 L bioreactor (BiostatC, B.Braun Biotech 
International, Germany) using basal salt medium (for recipe, see Appendix). The 
temperature and pH were kept constant at 30°C and 5.6 respectively. The pH was 
maintained by using 12.5% (v/v) NH4OH. The cells were grown in batch phase on 
glycerol as sole carbon source. A fed-batch production phase was started, 38 h after 
glycerol phase, when a sudden increase of dissolved oxygen (DO) was observed, 
indicating the decrease of respiratory activity and hence total consumption of glycerol 
in the media. During the fed-batch production phase, cells were grown on methanol 
and the feed was added manually to maintain a level of 6 g/L methanol. Trace 
elements were also added in methanol feed [93]. All on-line data was obtained via an 
in-house software, RISP (Real time integrating software platform, Institute of 
Technical Chemistry, Leibniz University Hannover). To avoid the froth formation, 
anti-foam (TEGO® Antifoam KS911, Evonik) was added, when necessary.  
3.3.1. Online and offline measurement 
During the course of cultivation, aeration rate, oxygen transfer and CO2 evolution were 





with a cascade of agitation, air flow and finally enrichment of air with oxygen. The pH 
regulation was performed with 12.5% (v/v) NH4OH and 2 N phosphoric acid addition. 
Samples were collected, at different time points during the cultivation, to check the 
biomass and amount of expression. For optical density measurement, samples were 
collected from the cultures regularly and diluted to suitable extent (between OD600nm  
1-8) with 0.9% (w/v) saline solution. The optical density was measured at 600 nm 
wavelength via spectrophotometer (Uvikon, Kontron Instruments). For each sample 
three readings were observed and the mean was taken. 
3.3.2. Cell harvesting 
In shake flask experiments, induction phase spanned from 120 to 190 h after induction. 
During bioreactor cultivation, cells were harvested 136 hours after induction, at 
OD600 = 320. The culture was connected via tubing to the continuous-flow centrifuge 
unit (Centrifuge Stratus, Continous flow rotars, Heraeus) to obtain the biomass in the 
form of pellet. For about one week, samples were stored at −20°C and for longer terms 
at −80°C.  
3.3.3. Cell lysis 
For different purposes, different lysis techniques were adopted. To observe the product 
formation during the cultivation, glass beads (0.45 mm; Sigma G-8772) were used to 
lyse the cells. For purification at pilot scale, lysis was carried out using Microfluidizer 
(M110L, Microfluidics). Detailed protocols of the lysis are described in the Appendix.  
3.3.4. P. pastoris GS115 control cell culture 
As a control, P. pastoris GS115 cells without plasmid were grown in the defined 
medium in shake flask. The cells were harvested and the lysate was treated for the 
purification process likewise as that of the producing cell culture. The samples were 
collected at various points of this purification-like process to use as a background 
control for transmission electron microscopy analysis. 
3.4. Downstream processing of HBsAg 
After the successful production of HBsAg in P. pastoris under previously optimized 





purification protocol from Pointek et al. [94] and Lünsdorf et al. [75] was followed; 
however some modifications were made, where necessary. The Purification was done 
by using different chromatographic techniques. The complete process is summarized in 
the figure 3.1. 
 
 
Figure 3.1. Flow-sheet illustration of HBsAg purification. The three blocks represent 
three stages of purification i.e. preparation, capturing and intermediate purification and 
ultimately, polishing. After salt mediated PEG precipitation, the cell lysate is subjected to 
capturing based on hydrophobic interaction using fumed silica. The Aerosil eluate is 
proceeded with ion exchange chromatography (IEX) to remove further contaminants. The 
semi-purified product is polished via size exclusion chromatography (SEC) and treated 
with KSCN. Final product is filtered and stored at 4°C till further analysis. 
 
Production of HBsAg in Pichia pastoris GS115
Cell lysis by Microfluidizer
PEG precipitation (16-18 h)
Aerosil 380 adsorption, washing and elution
Separation using DEAE sepharose FF (IEX)
Polishing via gel filtration (SEC) 







The biomass from the cultivation (100 g) was resuspended in the lysis buffer [25 mM 
sodium phosphate buffer, pH 8, 5 mM EDTA] to adjust OD600 ≈ 200. Afterwards, 
Tween 20 was added to adjust a final concentration of 0.6 % (v/v) and the pH was 
readjusted to 8.0. The mixture was passed through Microfluidizer at a pressure of 
12,000 psi and ~4°C, 12-14 times. Complete lysis was confirmed by viewing the cell 
lysate under the microscope. 
Polyethylene glycol 6000 (PEG 6000) was slowly added to the cell lysate to a final 
concentration of 5% (w/v) followed by the addition of 5 M NaCl to obtain a final 
concentration of 500 mM, in about half an hour keeping the mixture at 4°C. The 
mixture was stirred for 2 h and the precipitation was allowed to occur for 12-16 h at 
4°C. This suspension was clarified by centrifuging at 4°C and 4,000 rpm (3,345 × g) 
for 25 min.  
3.4.2. Capturing and intermediate purification  
The PEG supernatant was added to pre-equilibrated slurry of Aerosil 380 (Evonik, 
Hanau, Germany) in the binding buffer [25 mM sodium phosphate buffer, pH 7.2, 
500 mM NaCl]. To pre-equilibrate, the Aerosil was gently mixed in the binding buffer 
[0.13 g Aerosil per 1 g wet biomass] and centrifuged at 4,000 rpm (3,345 × g). The 
supernatant was discarded and the Aerosil pellet was resuspended in the binding buffer 
(e.g. 10 g + 500 mL buffer). The suspension obtained by mixing the PEG supernatant 
and the Aerosil pellet was stirred at 4°C and 300 rpm. After 4 hours, the Aerosil 
suspension was centrifuged at 4°C and 4000 rpm (3,345 × g) for 25 min. The pellet 
was washed twice using the wash buffer [25 mM phosphate buffer, pH 7.2], 
resuspended in the elution buffer [50 mM sodium carbonate-bi-carbonate buffer, pH 
10.8, 1.2 M urea] and incubated for 12 h at 37°C and 120 rpm. Aerosil eluate 
(supernatant fraction) was separated from the pellet after centrifugation for 150 min at 
25°C and 10,000 rpm (8664.5 × g) and clarified by vacuum-filtration (0.2 µm pore 
size). 
The filtered eluate was stored at 4°C for 24 h to improve stability of HBsAg, a 
phenomenon often referred to as the aging. Later this eluate was loaded on anionic 





ddH2O and 25 mM sodium carbonate-bicarbonate buffer, pH 8.0. The self-packed 
column was washed with and the HBsAg was eluted with elution buffer [50 mM Tris-
HCl buffer, pH 8.0, 500 mM NaCl]. The fractions containing HBsAg were pooled and 
concentrated using ultrafiltration concentrator of 10 kDa cut off (Vivaspin membrane 
10,000 MWCO, Sartorius Stedium Biotech GmbH, Germany). The protocol for ion 
exchange chromatography is reported in the Appendix. 
3.4.3. Polishing  
The HBsAg concentrate was loaded on pre-equilibrated gel filtration (GF) column 
[Sephacryl-S300, 26/60, GE healthcare] and eluted with the phosphate buffered saline, 
pH 7.2 [137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.76 mM KH2PO4, pH 7.2] at 
1 mL/min flow rate. The protocol for size exclusion is described in the Appendix. The 
fractions containing HBsAg were pooled and treated with KSCN, to a final molarity of 
1.2 M, for partial defolding. This mixture was incubated at 100 rpm and 37°C for 5 h 
in an orbital shaker. 
The KSCN treated HBsAg was dialyzed against phosphate buffered saline, pH 7.2 
(PBS, pH 7.2) using a membrane of cut-off size of 14 kDa (Cellulose acetate 
membrane, Visking, Carl-Roth, Karlsruhe). The purified VLPs were filter-sterilized 
(0.2 µm pore size) and stored at 4°C. 
3.5. General analytical methods for HBsAg estimation 
In this part of the experimental work, several analytical techniques were used to 
evaluate the purified HBsAg VLPs. Later, different steps during the downstream 
processing were probed to find out the crucial stages for VLP assembly and this was 
performed by electron microscopy. 
3.5.1. SDS-PAGE analysis 
Samples collected during the time points of cultivation were lysed with glass beads 
(0.45 mm; Sigma G-8772) by vortexing 8 times and incubating on ice successively. 
The lysates were boiled with equal volume of the sample buffer [10 mM Tris-HCl, 
pH 6.8, 1 mM EDTA, 2.5% (w/v) SDS, 0.2% Bromophenol blue, 45% (v/v) β-
mercaptoethanol, 5% (v/v) glycerol], vortexed for 1 min and boiled for 10 min at 





The gel was stained overnight with the colloidal coomassie [95]. Silver staining was 
performed to examine the purity of final product. 
3.5.2. Western blot 
The cell lysate was analyzed via Western blot to verify the presence of HBsAg. The 
sample was electro-transferred from SDS-PAGE to equilibrated PVDF membrane for 
30 minutes. The transfer was verified by the prestained kaleidoscope marker. The 
membrane was fixed in the blocking buffer and incubated with the primary antibody 
for 1 h. A mouse monoclonal anti-HBsAg antibody was used which is linear epitope 
specific. This blot was incubated for 1 h with goat-anti mouse secondary antibody and 
later developed using insoluble TMB substrate (Sigma-Aldrich, Germany). The 
reaction was stopped after visualization of bands by washing the membrane in ddH2O, 
for two to four times. 
3.5.3. ELISA analysis 
The samples taken from different time points during the cultivation and after the 
purification were analyzed for the estimation of soluble HBsAg by ELISA kit 
(Hepanostika micro ELISA, bioMérieux France). Cell pellets of the samples collected 
at time points during the cultivation with OD600 = 100 were lysed using a lysis buffer 
containing Tween 20 (Polysorbate) to a final concentration of 0.6% (v/v). All the 
samples were diluted appropriately with PBS, pH 7.2 and the antibody specific for an 
epitope between the amino acids 175-186 of S protein (present outside the so called a-
determinant region) was used to bind the antigen [96]. According to the manufacturer’s 
instruction, 100 µL of each controls, positive and negative, and samples at appropriate 
dilutions were loaded on the ELISA plate and incubated at 37°C for 1 h. 50 µL of the 
conjugate was added to the above and incubated at 37°C for 1 h. Washed the wells 6 
times with PBS, added 100 µL of substrate (Urea Peroxide + H2O2) and incubated at 
RT for 30 min. An HRP labeled anti-HBs conjugate was used to develop the signal. 
100 µL of 1 M H2SO4 was added as stopper and the plate was scanned at 450 nm. 
3.5.4. Protein concentration estimation 
Total protein contents were estimated by Pierce bicinchoninic acid (BCA) method 
(Pierce BCA protein Assay kit, Thermo Fisher Scientific). For pure HBsAg samples, 










All protein determinations were performed in triplicates. 
3.5.5. RP-HPLC analysis 
The HBsAg in crude cell lysate was quantitatively measured via reverse phase-High 
performance liquid chromatography (RP-HPLC). The lysate was treated with the 
solubilizing buffer, 8% (w/v) SDS, 50% (v/v) β-mercaptoethanol, 1 M DTT [97]. The 
RP-HPLC protocol is given in the Appendix.  
3.6. Electron microscopic analysis 
In order to confirm the presence of VLPs, initially, and later for the characterization, 
electron microscope techniques were used. 
3.6.1. Scanning electron microscopy (SEM) protocol 
Scanning electron microscopy (FEI Quanta 200, EDAX XL 30) was used to obtain 
images of purified HBsAg. Pure HBsAg (0.8 mg/mL) in PBS, pH 7.2, was used to 
prepare the grids. The grid was allowed to dry out overnight at room temperature and 
at next day was observed by SEM.  
3.6.2. Transmission electron microscopy (TEM) protocol 
The samples after downstream processing were analyzed using the energy-filtered 
transmission electron microscope Libra 120 (Zeiss, Oberkochen, Germany). Purified 
HBsAg VLPs were diluted with PBS, pH 7.2 to an appropriate protein concentration 
(0.2 mg/mL), adsorbed for 1 minute to a glow-discharged CFormvar foil and 
negatively stained with 2% (w/v) uranylacetate, pH 4.5. The zero-loss images, under 
the surveyance of realtime FFT (iTEM software, OSIS, Münster, Germany), were 
taken with a 2048 × 2048 CCD camera (Tröndle, Moorenweis, Germany) using a slit-
width of 15 eV and an objective aperture of 60 µm. The samples collected during the 
downstream processing were diluted to a suitable dilution (0.2 – 0.5 mg/mL) and 






Figure 3.2. The scheme for control experiments to monitor the effect of collective 
background on HBsAg VLP assembly. In control-1 (left hand side), P. pastoris GS115 
cells were lysed via Microfluidizer and the lysate was treated for purification process in 
same way as the routine purification procedure. In control-2 (right hand side), the 
P. pastoris GS115 samples collected at each step during control-2 were supplemented 
with HBsAg VLPs and allowed to stand overnight at 4°C. 
For monitoring the background structures and effect of the milieu on VLP 
morphology, five control experiments were carried out. P. pastoris GS115 cells (non-
producing) were grown in defined media and the lysate was treated in the same way as 
the purification process of HBsAg-producing P. pastoris cell lysate. The samples 
collected at each point were named as control-1 (Figure 3.2, left hand side). In a 
parallel control, the purified VLPs were added in samples from P. pastoris GS115 
lysate during control-1 and were incubated at 4°C for 24 h (Figure 3.2, right hand 
side). These samples were taken as control-2 and the TEM images were captured. The 
samples in control-2 experiment were supplemented with purified VLPs according to 
the percent contents of HBsAg in initial four steps of routine downstream process. For 
example in the producing cell lysate, 11 % of the total protein contents is HBsAg, so in 
the corresponding control-1 sample, purified VLPs were added to obtain 11 % HBsAg 
concentration. Finally, all the samples (control-1 and control-2) were diluted to get the 
total protein concentration of 0.2 mg/mL.  
Same procedure was applied to investigate the effect of purification buffers pertaining 
to initial four steps (control-3), with a parallel control in storage buffer, PBS, pH 7.2 
Growth of non- producing P. pastoris GS115
Cell lysis by Microfluidizer
PEG precipitation (16-18 h)
Aerosil 380 adsorption





(control-4). Before acquiring the TEM images, the samples were diluted to appropriate 
concentration (ranging from 0.2 mg/mL to 0.5 mg/mL). 
For the concluding control experiments, the cells were lysed in the routine lysis buffer 
as well as in the absence of all constituents one by one. Lysis buffer contains 25 mM 
PB, pH 8.0; 5 mM EDTA and 0.6% Tween 20. The resulting control lysate samples 
were used in TEM analysis, with a final protein concentration of 0.5 mg/mL. These 
control lysis (CL) samples are denoted as CL-1, CL-2, CL-3 and CL-4, hereafter. The 
outline of control-5 is explained in the figure 3.3. 
 
Figure 3.3. Outline of the control experiment for the effect of Tween 20 and EDTA. Here, 
LB stands for the lysis buffer. The control lysate samples are referred to as CL-1, CL-2, 
CL-3 and CL-4.  
For all the TEM analyses, samples were stored at 4°C, and analyzed not later than one 
week. 
3.6.3. Image processing for TEM 
TEM images were analyzed to measure average VLP size (diameter) and VLP count. 
An in-house software (Graphic analyzer, Patrick Lindner, TCI, Leibniz University of 
Hannover), was used to measure the average diameter and count of purified HBsAg 
VLPs. The detailed protocol is described in the Appendix. For more complicated 
samples, containing host cell components or VLP agglomerates, the VLP count was 
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3.7. Fluorescence spectroscopy for stability experiments 
The structural stability of HBsAg VLPs as a function of the concentration of 
denaturing agent was monitored by observing the fluorescence properties, both 
intrinsic as well as extrinsic. 
3.7.1. Intrinsic fluorescence measurements 
The fluorescence emission spectra were obtained employing LS 50B Luminescence 
spectrophotometer with Xenon discharge lamp as light source (PerkinElmer Ltd., 
United Kingdom). The samples were diluted to a concentration of 2 µM HBsAg VLP 
and excited at 280 nm. The resulting intrinsic extrinsic spectra were recorded using 
single scan mode (a cumulative average of 10 measurements) between 300-450 nm. 
The slit width for both excitation and emission measurements was kept at 5 nm. 
Temperature was kept constant at 25°C by using circulating water bath (Frigomix R, 
B. Braun Biotech International, Germany).  
3.7.2. Extrinsic fluorescence measurements 
The extrinsic fluorescence measurements were performed similar to the intrinsic 
fluorescence. The samples were excited at 400 nm and spectra were scanned between 
430-550 nm. The rest of parameters were kept the same. Bis-ANS (4,4′-Dianilino-1,1′-
binaphthyl-5,5′-disulfonic acid, Sigma-Aldrich) was used to bind with hydrophobic 
sites of HBsAg VLPs. Following concentration of HBsAg (with respect to VLP) was 
used for the formation of complex. 
2 µM HBsAg : 20 µM Bis-ANS 
A stock solution of 1 mM bis-ANS in DMSO was prepared and stored in dark at room 
temperature. The final concentration of bis-ANS was determined by measuring the 





3.7.3. Defolding studies via fluorescence spectroscopy 
Defolding series was performed with three denaturing salts, namely, guanidine 
thiocyanate (GdnSCN), potassium thiocyanate (KSCN) and guanidine hydrochloride 





[0.8 mg/mL i.e., 30 µM] was treated with series of chaotropic salts (GdnSCN, KSCN 
and GdnHCl) to obtain a final concentration of 0.2 µM and allowed to stand at 25°C 
for 3 min. The sample were excited at 280 nm and then scanned for the fluorescence. 
For denaturing measurements using extrinsic fluorescence properties, the purified 
HBsAg (2 µM) was mixed with bis-ANS (20 µM) and left for at least 10 min. The 
complex (HBsAg.bis-ANS) was then mixed with chaotropic salts (series of GdnSCN, 
KSCN and GdnHCl), allowed to stand for incubation and scanned after being excited 
at 400 nm. The preliminary experiments showed that the trend in defolding curve 
remains the same after 3 min and 24 h, therefore rest of the measurements were done 
with 3 min incubation time. 
3.7.4. Data analysis 
All the measurements were normalized before being processed for graphical form. For 
normalization, the fluorescence intensity in absence of any chaotropic agent was taken 
as the standard and the rest of readings were taken as a ratio with respect to it. 
In order to characterize the hydrophobic regions, Stern-Volmer equation was used. 
F 0⁄ F=1+KSV [Q] 
Equation 3.1: Stern-Volmer relation 
Here, F0 and F are the fluorescence intensities in the absence and presence of 
quenchers, KSV is the Stern-Volmer quenching constant (M
−1
) and [Q] is the 
concentration of the quencher. 
All the fluorescence data obtained was normalized by taking a ratio between intrinsic 
fluorescence value in the absence (F°) and presence (F) of any chaotropic agent.  
3.8. VLP determination using the Virus counter 
To verify the defolding curves obtained via fluorescence spectroscopy, HBsAg VLPs 
were analyzed using the virus counter, ViroCyt 2100 (InDevR Inc. USA). Virocyt is a 
specialized flow cytometer designed specifically for viruses. It works on the same 
principle as that of flow cytometer and has two photomultiplier tubes (PMT), one for 





One unique feature of flow cytometry is that it measures fluorescence per cell or 
particle. This contrasts with spectrophotometry in which the percent absorption and 
transmission of specific wavelengths of light is measured for a bulk volume of sample.  
3.8.1. Sample preparation 
For the sample preparation, the dye kit from instrument’s manufacturer was used. The 
composition of most of the components of the kit is confidential. The stock solution of 
HBsAg VLPs consists of 30 µM [0.8 mg/mL] from which a further dilution of 2 µM is 
being prepared. From initial experiment, it was concluded that a dilution of 1:100 was 
optimal for measuring the samples. Since for the normal fluorescence measurements, 
the dilution factor is roughly 15 times, a further dilution of ≈6 times is required to get a 
final dilution of a factor 100.  
The HBsAg VLP stock solution was mixed with the denaturant solution (GdnSCN, 
KSCN) to get a total volume of 60 µL and left for 3 min at 25°C. This mixture was 
further diluted with 240 µL of SDB (sample dilution buffer) to make the total volume 
300 µL and a final concentration of 2 µM HBsAg VLPs. 150 µL of combo dye was 
added in this final mixture [a 2:1 sample to dye ratio]. The samples were incubated at 
ambient temperature for at least 30 min in dark prior to analysis.  
3.8.2. Measurement protocol for Virus counter 
Before staring the measurements, the instrument was validated for cleanliness and 
performance. First the inter sample wash [ISW] was run followed by cleanliness 
verification fluid [CVF]. Then the performance validation standard was run to check 
the performance status. After validation, samples were analyzed using the standard 
settings i.e., flow rate: ~3700-6500 nL/min; Pressure: 15 psi; Threshold for nucleic 
acid: 0.34 - 0.75 [PMT signal (V)] and for protein 0.57 – 1.76 [PMT signal (V)] 
3.9. VLP analysis using dynamic light scattering 
The stability of HBsAg VLPs was studied by monitoring of their size as a function of 
concentration of the chaotropic salts via dynamic light scattering (DLS). The 
instrument used for this purpose was DynaPro Titan with software Dynamics V6 
(Wyatt Technology, Europe). The source of light for illumination is a semiconductor 





3.9.1. Sample preparation 
The samples were prepared in a similar manner as that for fluorescence studies. The 
VLP stock solution consists of 10 µM HBsAg VLPs. The stock solution was mixed 
with dilution series of chaotropic agents (GdnSCN, KSCN, GdnHCl) to give a final 
concentration of 2 µM HBsAg VLP, allowed to stand for 3 minutes at 25°C and 
analyzed via the DLS instrument.  
3.9.2. Measurement protocol for DLS 
The parameters for the DLS measurements are given in the table 1.  
Variables Specification 
Acquisition time 5 sec 
Acquisition number 30 
Cut offs 5,150 
Laser intensity Adjusted accordingly 
Model: Rayleigh sphere 
Sample (model) Globular protein 
Temperature 25°C 
Table 3.1. The instrument settings applied for DLS measurement of the HBsAg VLPs for 
the purpose of stability studies. 
All the measurements were done in duplicates. During the whole set up, temperature 
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4. Results and discussion 
Vaccines, whether prophylactic or therapeutic play an important role in preventing 
several diseases and hence to enhance the general quality of the living. VLP vaccines 
being non-infectious and relatively economical are candidate against many illnesses. In 
this thesis, hepatitis B surface antigen (HBsAg) VLPs are used as the model system to 
study the in vitro self-assembly process. The main goal of this study is to elucidate the 
mechanism of VLP assembly and to characterize the structure of assembled particles.  
In previous sections, the theoretical aspects of the project and experimental methods 
were described. In this chapter, the final results of performed experiments will be 
reported. Alongside, these findings will be discussed in details and ultimately 
concluded in the end. For convenience, the work has been divided into three main 
sections, namely,  
- Production and purification of HBsAg 
- TEM analysis during downstream procedure to monitor in vitro assembly process 
- Stability studies of HBsAg via different analytical techniques 
4.1. Production in Pichia pastoris GS115 and downstream 
process of recombinant hepatitis B surface antigen 
virus-like particles 
In the first stage of experimental work, cultivation parameters were optimized to 
generate HBsAg in the methylotrophic yeast, Pichia pastoris. The P. pastoris cells 
were cultivated at different scales to monitor the reproducibility of the system. The 
cells were lysed and the downstream process was carried out to obtain pure HBsAg 
VLPs. 
4.1.1. Shake flask cultivation 
For the preliminary expression tests of HBsAg in P. pastoris, defined, semi-defined 
and complex media were tested at shake flask scale. During all the cultivations, 
temperature and agitation were kept constant at 30°C and 250 rpm respectively. The 
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cells were allowed to grow till OD600 = 2-6 on glycerol as the sole carbon source. The 
cultures were induced with 0.5% methanol when the stationary phase started. Several 
samples were collected during the cultivation at regular intervals (e.g., 0 h, 24 h, 48 h, 
92 h, and 120 h). During the initial shake flask cultivations, no significant increase in 
the product yield was observed after 120 h post-induction period. Therefore the later 
cultures were harvested 120 h after inducing with methanol. 
 
Figure 4.1. Growth curves of the shake flask cultivations for optimization of the HBsAg 
production. All the cultivations were done at least in triplicate at 30°C and 250 rpm. Left 
box represents growth curves in complex buffered media, BMG and BMGY. Middle and 
right box shows growth trend in defined (DM) and semi-defined media (semi-DM), 
respectively. 
A higher growth rate was observed in the semi-defined media as compared to in the 
defined media, despite of less product expression. The basal salt media (defined media 
A) showed medium cell density with a growth rate of 0.08 h
-1 
during the exponential 
phase. In the defined medium, a common problem to cope with was lower pH value. 
This problem was observed in defined as well as in semi-defined media i.e., from pH 
6.0 in the beginning to pH 3-4 towards the end of cultivation. This situation was tried 
to overcome by adding 25% (v/v) NH4OH every 24 h, to readjust the pH 6.0, measured 
by pH strips. On the other hand the complex media, due to presence of a buffer system, 
maintained pH 6.0 till the harvest.  
Surprisingly, the semi-defined media which showed a growth rate of 0.034 h
-1 
during 
the exponential phase demonstrated least amount of HBsAg expression. In context of 
expression level, the buffered-minimal glycerol media (BMG) was observed to be 
most efficient. This may be due to the fact that complex media contain rich nutrient 
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supplements like peptone and yeast extract which ensure a higher expression of the 
product. 
 BMG BMGY DM-A DM-B Semi-DM 
P. Pastoris HBsAg 0.01 0.01 0.01 0.01 0.04 
P. pastoris GS115 0.01 0.01 0.01 0.01 0.03 
Table 4.1. Growth rates of P. pastoris in different media after the onset of methanol 
phase. 
As a comparison, growth rates during the whole methanol phase are being summarized 
in table 4.1.  
 
Figure 4.2. SDS-PAGE analysis of HBsAg expression in 1 L cultivation in BMG. The 
culture was induced with 0.5% MeOH, after every 24 h. Box A and B contain images of 
the two gels developed with colloidal coomassie and silver staining respectively. Arrows 
show the HBsAg monomer band. 
After comparing all the media for expression, basal salt media (defined media A) was 
chosen to continue to produce HBsAg in P. pastoris at bioreactor level. Basal salt 
media was chosen because of its reproducibility and in spite being simple its ability to 
produce HBsAg, under controlled pH. Moreover it contains specific components such 
as, MgSO4.7H2O and Yeast Trace Metal elements (YTM), which are important for 
growth of P. pastoris culture.  
4.1.2. Bioreactor cultivation 
The cells were grown in batch phase using glycerol as the carbon source till OD600 = 
200. The production phase was started when a sudden increase in dissolved oxygen 
was observed due to the fact that the cells consumed all the glycerol present in media. 
At this point, methanol was added to the cultivation as the carbon source. The 
A B
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methanol concentration required per day for the HBsAg-producing P. pastoris 
cultivation was calculated according to the previous cultivations [93] and YTM 
containing methanol feed was added manually at each 8 h interval to maintain a level 
of 6 g/L. The biomass was measured by observing OD600 every 2-3 hours before and 
every 8 h after induction.  
 
Figure 4.3. P. pastoris cultivation before and after induction (separated by the red dotted 
line) in a 10 L bioreactor. Cascade agitation and continuous air flow (green line) was used 
to keep the dissolved oxygen level constant. Here methanol was added manually at every 
8 h to keep the level at 6 g/L.  
The cells were harvested 136 h after induction at OD600 ≈ 330. The cells were spun 
down, washed with the phosphate buffer, pH 7.2 and resuspended in the lysis buffer 
(for recipes, refer to the Appendix). The growth rate (μ) during growth on glycerol and 
on tmethanol was recorded as 0.134 h
−1




Figure 4.4. SDS-PAGE of the samples collected during the bioreactor cultivation time 
points. Gel A consists of the soluble fractions whereas gel B of the whole cell lysates. 
Lane 1 corresponds to the sample taken before induction. Starting from lane 2 to 14, each 
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sample was collected with 8 h difference. The dotted box indicates monomer band of 
HBsAg. 
The high cell density cultivation of P. pastoris was evaluated by examining the 
samples collected at various time points for the HBsAg expression. The SDS-PAGE of 
cell lysates shows a significantly high expression of HBsAg, present in form of 
monomer of 25 kDa and dimer of 48 kDa size (figure 4.4). 
4.1.2.1. RP-HPLC  
The cell lysate from producing and non-producing cultivations was treated with the 
solubilizing buffer before analyzing via reverse phase-high performance liquid 
chromatography (RP-HPLC) to investigate the presence of HBsAg.  
 
Figure 4.5. Reverse-phase HPLC analysis of HBsAg in the cell lysate, treated with the 
solubilizing buffer. The pink line represents cell lysate from the non-producing P. pastoris 
GS115 cultivation. The green line represents the HBsAg producing P. pastoris GS115 
cultivation. 
The RP-HPLC results represent total (soluble and insoluble) HBsAg, as the sample 
was solubilized under denaturing conditions. To analyze the soluble fraction, Western 
blot and ELISA test were performed.  
4.1.2.2. Western blot 
The Western blot under reducing conditions was performed to confirm the expression 
of HBsAg the in P. pastoris cultivation. A mouse monoclonal anti-HBsAg antibody 
against HBsAg was used to reveal the respective band. This monoclonal antibody is 
linear epitope specific for HBsAg (a kind gift from Navin Khanna, ICGEB India). 
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Figure 4.6. The Western blot analysis of P. pastoris total cell lysate: Well A consists of 
the whole cell lysate of non-producing P. pastoris GS115 whereas the well B shows lysate 
from HBsAg producing culture. 
The Western blot analysis, of HBsAg-producing P. pastoris cell lysate (with non-
producing P. pastoris cell lysate as a negative control), confirms the presence of 
HBsAg. The band for subunit dimer indicates the presence of disulfide bonds which 
are prerequisite for the VLP assembly. 
4.1.2.3. ELISA analysis 
The antigenicity of HBsAg was tested by ELISA. The soluble HBsAg in cell lysate 
(biomass = 100 OD600) was analyzed by ELISA kit. All the samples were diluted by 
factor of 1000-2000 with PBS, pH 7.2. 
 
Figure 4.7. ELISA test of HBsAg in cell lysates. Soluble HBsAg contents from samples 
collected at cultivation time points after the induction phase are shown (OD600nm=100). In 
the inset, HBsAg standard curve to quantify the soluble protein contents is shown.  
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According to ELISA result, the presence of HBsAg is observed from 8 hours after the 
induction phase of cultivation. The amount of HBsAg per 100 OD of cell pellet does 
not increase extensively (Figure 4.7), although, an effective increase in protein 
concentration is observed due to increase in total biomass (Figure 4.3). 
4.1.3. Downstream processing of HBsAg 
Downstream processing is arguably the most important part of a production method. 
Each step leads to higher purity of the desired product but at the same time a loss in the 
yield. A compromise ought to be made between the required purity and the obtained 
yield. In general, the downstream process for all the yeast derived HBsAg consists of 
similar procedure. The cells, after the lysis, are processed with multiple 
chromatographic steps and finally polished to proceed for the morphological analysis. 
4.1.3.1. PEG precipitation 
The cells after cultivation were spun down, washed with the phosphate buffer, pH 7.2 
and 100 g biomass was resuspended in lysis buffer (for recipe, refer to the Appendix). 
The lysis was performed via Microfluidizer, using 12,000 psi pressure and 12-14 
cycles. The crude whole cell lysate was subjected to PEG precipitation in the presence 
of high salt concentration. All the hydrophilic proteins were precipitated (a 
phenomenon known as salting out) as a result of PEG addition. Unlike typical PEG 
precipitation, here the supernatant contains the product of interest. The presence of at 
least 500 mM NaCl has been suggested as vital for the efficiency of sedimentation. 
About 5% (w/v) or more PEG helps also to get rid of DNA by co-precipitating it [99]. 
The mechanism of PEG precipitation is not fully understood. It has been proposed that 
the process of precipitation occurs as a result of displacement of precipitant from the 
solution and consequently salting out [100].  
4.1.3.2. Adsorption on Aerosil 380 
After PEG precipitation, the resulting supernatant was adsorbed on the fumed silica, 
Aerosil 380. The principle involved in the purification based on hydrophobic 
interaction forces is that hydrophobic part of a protein binds to the hydrophobic 
stationary phase. In this work, Aerosil 380 has been used as the capturing material onto 
which the proteins adsorb according to their hydrophobicity. The non-adsorbed 
contents, called as Aerosil flow through, were discarded. Further contaminants were 
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removed with washing steps and the proteins were desorbed from Aerosil in the urea 
containing elution buffer. The Aerosil eluate was filtered (0.2 µm pore size) to make 
sure the complete removal of silica particles. The eluate was stored at 4°C for 24 h for 
aging purpose which renders stability to HBsAg and was later loaded on DEAE resin.  
4.1.3.3. Ion exchange chromatography 
150 ml of the Aerosil eluate (0.88 mg/mL), after aging, was proceeded for the anionic 
exchange chromatography. Here a self-packed column of FF Sepharose resin (≈20 mL 
CV) was used for the chromatography. This step removed essentially the host system 
contaminants and the remaining silica particles, if any. For pooling, only those 
fractions were selected which contained bands corresponding to the HBsAg mono- and 
dimer. The protocol for size exclusion chromatography of HBsAg is described in the 
Appendix. 
 
Figure 4.8. Ion exchange chromatography profile of Aerosil eluate using DEAE 
Sepharose FF ion exchange beads (A). SDS-PAGE of fractions corresponding to the peak 
is shown in the panel B. Here “load” correspond to the sample loaded on the IEX resin.  
At the end of ion exchange chromatography, relatively concentrated protein sample is 
obtained because of binding on the anionic exchange resin and efficiently narrow 
elution with 500 mM NaCl. However pooling of all the fractions, belonging to the 
HBsAg peak, gives a low concentration of final sample (Figure 4.10, lane 8).  
4.1.3.4. Size exclusion chromatography 
Since size exclusion chromatography has a dilution effect on the protein fractions, the 
pooled sample from IEX was concentration using ultrafiltration concentrator column 
(Vivaspin membrane 10,000 MWCO). 15 mL of this concentrated pooled fraction 
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(4.26 mg/mL) obtained after anion exchange chromatography was loaded on the gel 
filtration (GF) column to separate well-defined VLPs from the aggregates. Phosphate 
buffered saline (PBS), pH 7.2 was used as the mobile phase. It is known that, due to 
their large size, the HBsAg VLPs appear within 20% of void volume whereas the 
aggregates, along with other host cell proteins, show up later as a second peak or as a 
tailing (Figure 4.9), depending essentially on the separation efficiency of stationary 
phase. The protocol for size exclusion chromatography is given in the Appendix. 
 
Figure 4.9. The purification step of HBsAg via size exclusion chromatography. (A) The 
peak appearing in 20 % void volume correlates to the HBsAg VLPs. The tailing of the 
peak belongs to non-VLP form and .P. pastoris proteins. Lower panel (B) shows SDS-
PAGE of corresponding fractions stained with the colloidal coomassie. 
The GF fractions including mono- and dimer bands were pooled to process further. 
The pooled fractions were concentrated using the ultrafiltration concentrator column 
(Vivaspin membrane 10,000 MWCO, Sartorius Stedium Biotech GmbH, Germany). 
After the gel filtration step, a significantly pure protein is obtained (Figure 4.10). 
4.1.3.5. KSCN treatment 
The fractions corresponding to the HBsAg VLPs were collected and the pool was 
treated with KSCN to a final molarity of 1.2 M. Treatment of the purified protein with 
Ep502- HBsAg Purification 
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KSCN is reported to improve the tertiary structure by increasing the disulfide bonding 
[101]. Zhao et al. has reported that an increase in the antigenicity of HBsAg VLPs, 
after the KSCN treatment, has been observed due to increased cross-linking, which is a 
result of the rearrangement in the mis-matched disulfide bonds [86]. 
To remove the KSCN and other salts, the purified HBsAg was dialyzed against PBS, 
pH 7.2 at least thrice with ≥900 times volume of the purified sample to be dialyzed. 
Finally the purified product was collected and further analyzed. 
The presence of HBsAg was verified by the ELISA and purity by 12 % SDS-PAGE 
under the denaturing conditions (Figure 4.10-B). Two bands corresponding to the 
mono- and dimer were observed around 25 and 50 kDa respectively. Even the presence 
of SDS and β-Merceptoethanol was not able to break all the disulfide bonds, 
explaining the presence of a dimer band around 50 kDa in SDS-PAGE analyses 
(Figure 4.10).  
 
Figure 4.10. SDS-PAGE of the samples collected during the entire downstream 
procedure. 1: Whole cell lysate; 2: Soluble fraction of cell lysate; 3: PEG supernatant; 4: 
Aerosil flow through (unbound fraction); 5: Aerosil wash 1; 6: Aerosil wash 2; 7: Aerosil 
eluate; 8: DEAE load; 9: DEAE pool (collective fractions of HBsAg containing peak); 10: 
GF load; 11: GF pool (of HBsAg containing fractions); 12: purified HBsAg after KSCN 
treatment. Lane 13 shows the purified product 5X concentrated, showing bands for mono- 
and dimeric form. Note that the first sample was diluted 3X and next three 2X with the 
sample buffer. The gel was stained overnight with the colloidal coomassie dye. 
The purity of product can be observed in the SDS-PAGE where 5 times concentrated 
sample was loaded (Figure 4.10, lane 13).  
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4.1.4. Protein concentration 
The extent of HBsAg purity increases considerably after each step of the downstream 
process. The step by step proportion between the contaminants and the product was 
calculated via densitometry. These figures are shown in the percentage (Figure 4.11, 
panel A). 
Protein estimation during the downstream process depicts in average 30% loss of the 
product during the initial steps i.e. PEG precipitation and treatment with Aerosil 
(Figure 4.8). Overall, 1-2 percent of the total HBsAg could be recovered by the end of 
the purification process (Figure 4.11, panel B). 
 
Figure 4.11: Summary of the downstream process in terms of protein contents and 
HBsAg purity. In upper panel (A), the graph corresponds to the percentage ratio between 
product and contaminants contents. The black bars represent host cell proteins (HCPs) and 
the grey bars stand for the total HBsAg. The last bars show the purity of final product. In 
lower panel (B), the percent yield of HBsAg after the major purification steps is shown. 
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The concentrations of purified HBsAg via BCA assay and ELISA are 0.25 mg/mL and 
0.28 mg/mL respectively. The final yield of HBsAg per preparative process is 12.5 mg 
(per 100 g biomass as the starting material). 
4.1.5. Electron microscopy of HBsAg 
The purified product was analyzed via scanning as well as transmission electron 
microscopy. No VLPs could be visualized via scanning electron microscopy (data not 
shown). This could be due to the fact that during the drying process before mounting, 
the VLPs may lose their structure. The results from TEM measurement were more 
promising as they not only showed the presence of VLP but also paved a way for 
further analysis. The results from TEM studies of HBsAg VLPs are discussed 
comprehensively in the coming section of this chapter. 
4.1.6. Conclusion 
In this section, the production and purification of HBsAg was described. It was 
observed by the SDS-PAGE analysis that the expression increases many fold while 
upscaling from shake flask to the bioreactor scale. HBsAg was produced in P. pastoris 
in a 10 L bioreactor using the defined medium. In purification process, most of the 
host cell components were removed during Aerosil adsoption step and anion exchange 
chromatography. The final yield of pure HBsAg is 12.5 mg/100 g WCW.  
The data from densitometry suggests that out of the total expressed proteins, 11 
percent is HBsAg. From this HBsAg, the major part is lost during PEG precipitation 
and Aerosil adsorption. The greatest loss is observed during the Aerosil treatment 
where more than 60% product is lost.  
The purified product was examined via SDS-PAGE, Western blot and ultimately 
TEM. SDS-PAGE shows the presence of HBsAg but not necessarily the VLPs. 
Western blot confirms the correct conformation of HBsAg but still does not prove the 
presence of VLP. The routine analytical techniques have a limitation to distinguish 
between single subunit and a VLP, therefore the most reliable method to verify the 
presence of VLPs is visualization by TEM. SEM could not examine the VLPS due to 
the nature of sample immobilization protocol.  
.
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4.2. Insight into the in vitro assembly process during 
downstream processing via TEM using HBsAg      
virus-like particles as a model case 
In the field of virology, electron microscopy (EM) has been the most prominent and 
pivotal technique. Developed in 1931, it gained popularity quickly pertaining to its 
applicability and versatility. Formerly, it was not possible to view the viruses with 
conventional microscopes. Transmission electron microscope (TEM) was the initial 
type of electron microscopy where the electron beam is transmitted through the thin 
preparation of sample. On the other hand, in scanning electron microscopy (SEM), the 
secondary electrons are used to generate the image. These are actually the emitted 
electrons after the striking of electron beam on the surface of object. 
With the magnification as high as 40,000 times, TEM provides the opportunity to 
actually visualize the viruses as well as proteins of the size up to 1 nm. There is no 
requirement of specialized or individualized staining techniques for each specimen. 
Usually the sample immobilized on the grid can be kept for years and is good to 
analyze even later. Apart from the diagnostics, TEM is also useful in the viral 
replication and assembly studies. In recent decades, EM has proved to be the key tool 
in the ultra-structural study of VLPs.  
4.2.1. TEM analysis of purified product 
In previous part, the cultivation of HBsAg producing P. pastoris GS115 cells and the 
downstream processing of biomass to obtain the purified product was described. The 
efficiency of purification was evaluated by analyzing the electron micrographs for the 
presence of VLPs. In general, the final purified product was observed to have no 









Figure 4.12. TEM image of the pure HBsAg VLPs after the downstream process. The 
VLPs were stored in PBS, pH 7.2 and later negatively stained with the 2% (w/v) uranyl 
acetate, pH 4.5. 
HBsAg VLPs of an average size (diameter) of 22 nm were observed in the purified 
sample (Figure 4.12). In this part of the work, numerous samples were collected during 
the crucial steps of purification procedure and their TEM images were captured for the 
VLP size and count estimation. 
4.2.2. Probing through downstream process via TEM  
As reported by Lünsdorf et al, VLPs are not present during the production stage inside 
the P. pastoris cells [75]. In this part, several steps throughout the purification 
procedure were probed for the VLP presence. Samples were collected at each step and 
analyzed via TEM. The stepwise layout of the purification protocol and corresponding 
TEM images are shown in the figure 4.13. As observed in the images, the steps in red 
Single VLPs 
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box do not show VLPs, except the last step i.e. Aerosil elution. The steps encircled in 
green box do show VLP occurrence, with the quality being improved progressively. 
 
Figure 4.13. A flow-sheet illustration of the HBsAg purification. The steps encircled in 
the red exhibit no or very few VLPs while the ones in the green do. A: Crude cell lysate; 
B: PEG supernatant; C: PEG supernatant adsorbed on Aerosil; D: Aerosil eluate; E: 
DEAE load; F: GF load; G: GF pool before KSCN treatment; H: HBsAg VLPs after 
KSCN treatment. Scale bar = 100 nm 
As described previously, there are no or negligible VLPs observed in the initial steps 
of purification (Figure 4.13, A-C). They appear for the first time in reasonable amount 
after the Aerosil elution step. Although the VLP count increases drastically after ion 
exchange chromatography, few contaminants are still observable until the size 
exclusion step.  
It was observed that in the middle steps (during Aerosil elution and IEX 
chromatography), though present in significant number, the VLPs tended to stick 
together in the form of clumps rather than single independent particle which portrays 
the hydrophobicity of immature VLPs. Moreover the VLPs posses better structure 
Production of HBsAg in P. pastoris GS115
Cell lysis by Microfluidizer
PEG precipitation 16-18 h)
Aerosil adsorption, washing and elution
Separation using DEAE sepharose (IEX) 
Polishing via gel filtration (SEC) 
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definition towards the end of purification, especially after the KSCN treatment 
(Figure 4.13, E-H). 
4.2.2.1. VLP size 
The size of VLPs during different steps of the downstream processing was investigated 
via Graphic analyzer. The average diameter (hydrodynamic) observed for the HBsAg 
VLPs was 22 nm ±2. The small deviation might be due to the fact that depending on 
the solvent, the hydrodynamic radius can differ from radius of gyration [84]. 
The size of VLPs remains more or less the same irrespective of their count during 
different steps. However, it is observed that the VLPs improve their uniformity in the 
size and geometry during the course of purification. In general, the VLPs observed in 
the initial stages, are less consistent in octahedral geometry. On the contrary, the VLPs 
obtained after the polishing step are more precise in their construction and their 
structure compactness, developed due to increased disulfide bonding, can be noticed in 
the TEM images. 
4.2.2.2. VLP morphology 
The shape and appearance of VLPs distinctly becomes improved and homogenous 
during the course of purification as the inter-subunit interactions are increased due to 
higher HBsAg purity and removal of detergent and denaturing components. The trend 
from clumping together to the single well-defined VLPs can be observed in the TEM 
images (Figure 4.13). The control experiment (Control 2 and 3) showed that even the 
good quality VLPs (from optimized purification protocol) tend to lose their structure 
when put under relevant milieu i.e. consisting of the HCCs and certain constituents in 
the buffer system such as Tween 20, EDTA and urea.  
In coming lines, the effect of various milieu factors on the morphology as well as 
count of the VLPs will be discussed comprehensively. For monitoring these factors, 
control experiments were performed, whose details can be found in chapter 3, section 
TEM protocol. For convenience these control experiments are stated here shortly. As 
standard, the samples from routine downstream process were examined via TEM. For 
background structures, GS115 cell lysate was treated with same protocol as that of 
routine HBsAg purification and the samples from this process were introduced with 
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purified HBsAg VLPs. These experiments were denoted as control-1 and control-2, 
respectively. The experiments pertaining to incubation of purified VLPs in purification 
buffer (for initial four purification steps) and storage buffer (PBS, pH 7.2) were named 
as control-3 and control-4, respectively. Lysis tests in various combinations of the lysis 
buffer components were called control-5. 
4.2.3. Control experiments for TEM background 
Several peculiar membranous structures were observed in the samples taken during the 
initial steps of downstream processing. Mostly, these structures have a cup-shaped 
appearance with a double membrane (Figure 4.14). To investigate whether these 
structures are arriving from HBsAg or not, positive and negative control experiments 
were performed. In control-1 experiment, non-producing P. pastoris GS115 cells were 
lysed and handled according to the routine purification protocol of HBsAg.  
 
Figure 4.14. Electron micrographs of samples corresponding to background control. A-D: 
Cup-shaped membranous structures found in P. pastoris lysate during routine purification 
of expression culture; A: micrograph of HBsAg producing P. pastoris lysate; B: PEG 
supernatant; C: PEG supernatant bound on Aerosil; D: Aerosil eluate;  
1-A – 1-D: Micrographs of corresponding samples from control-1 i.e. P. pastoris GS115 
cell lysate treated with the same procedure as that of routine protocol. Scale bar = 100 nm. 
The cup-shaped structures were observed also in the control samples irrespective of the 
presence or absence of HBsAg (Figure 4.14 1-A to 1-D). The TEM images of both of 
these controls are shown in figure 4.14. As these spherical structures exist also in non-
producing P. pastoris cell lysate, it was concluded that they do not arrive from HBsAg. 
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cell system; however, further investigation is required for the confirmation. The similar 
circular structures in P. pastoris lysate have been observed in previous studies as well 
[102].  
4.2.4. Effect of host cell components on VLPs 
In order to demonstrate the effects of host cell components (HCCs) present as 
contaminants in the lysate, control-2 was performed. In control-2, the P. pastoris 
GS115 lysate samples collected during the control-1 were supplemented with purified 
HBsAg VLPs and incubated for 24 h at 4°C. The study showed that the structure and 
compactness of intact VLPs is disturbed when they are added to corresponding 
samples from mock purification of P. pastoris GS115 lysate (control-1). Figure 4.15 
shows the comparison of samples collected during control-1 and their corresponding 
samples from control-2. 
 
Figure 4.15. TEM micrographs of the samples collected from control-1 and control-2. In 
control-1 purification (above), non-producing cells were lysed and processed for 
purification. In control-2 (below), the samples were supplemented with purified HBsAg 
VLPs and incubated for 24 h at 4°C. A: P. pastoris GS115 lysate; B: PEG supernatant; C: 
PEG supernatant bound on Aerosil; D: Aerosil eluate. TEM analysis was done to observe 
the changes in structure. Scale bar = 100 nm.  
There are two possibilities which explain this trend. Firstly, it can be due to the strong 
buffer system e.g., presence of detergents, high salt concentration and/or denaturants 
like urea. Second hypothesis involves the effect of protein-protein interaction. Many 
host cell components (HCCs) which are present as contaminants, at least in initial four 
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is present in amounts ranging from 1 mg/mL (crude cell lysate) to 0.5 mg/mL (Aerosil 
eluate). This may also be attributed to the negative effect of certain P. pastoris 
homologous proteins. However further experiments are required to investigate this 
effect in detail. 
The condition of VLP is greatly dependent on the milieu they are in at any particular 
moment. The system at initial stages is composed of buffers with high salt 
concentration and detergents in addition to HCPs which act as contaminant and 
constitute a large part of total protein contents. It might be assumed that all these 
factors result in an unfavorable environment for VLP assemble to occur. Due to this 
same reason, the intact VLPs are also distorted when put in this milieu for 24 h 
(Figure 4.15). 
4.2.5. Effect of solvent system on VLPs 
To probe further the influence of native proteins and buffer system, next experiments 
were performed to study the effect caused by the buffer system in isolation from that of 
HCPs. To pin down the decisive factor, VLPs were introduced into the buffer system 
of the initial four steps (control-3). To have a comparison, the same amount of protein 
was added to PBS, pH 7.2 and incubated (control-4). The VLP count is observed to be 
higher in PBS than in its parallel purification buffer system (Figure 4.16). The buffer 
composition of each sample is given in table 4.2. 
Sample Purification step Buffer composition pH 
3-A lysis 25 mM PB, 8.0, 5 mM EDTA, 
0.6% Tween 20 
8.0 
3-B PEG precipitation  lysis buffer, 500 mM NaCl, 
5% PEG 6000 
8.0 
3-C Aerosil binding 25 mM PB, 500 mM NaCl 7.2 
3-D Aerosil elution 50 mM CBB, 1.2 M Urea 10.8 
Table 4.2. The buffer composition of samples from control-3 experiment. In this control, 
the buffer systems from routine purification process were introduced by the purified 
HBsAg VLPs. The VLP containing samples were incubated at 4°C for 24 h and later 
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The results in figure 4.16 illustrate that the intact VLPs are disassembled when added 
to the purification buffer corresponding to the initial purification step. The difference 
between VLP count in a certain buffer and its twin sample in PBS is considerably 
vivid (Figure 4.17). Moreover, the remaining VLPs appear to be less compact and 
sticking together (Figure 4.16, 3-A – 3-D). Hence it can be concluded that due to the 
presence of detergent like Tween 20 and denaturant like urea and EDTA, the initial 
downstream steps do not offer a feasible environment for the VLP assembly as HBsAg 
subunits are surrounded by high concentration of denaturing salts. The impeding effect 
of EDTA and glycerol has been observed earlier in the Polyomavirus as well [78]. 
 
Figure 4.16. Effect of the buffer system on HBsAg VLP morphology. 3-A – 3-D are the 
micrographs from control-3 where purified VLPs were added to the purification buffers 
and allowed to stand for 24 h. The images shown here are of HBsAg VLPs in the lysis 
buffer (3-A), PEG precipitation buffer (3-B), Aerosil binding buffer (3-C) and Aerosil 
elution buffer (3-D). Samples 4-A – 4-D represent the corresponding protein contents in 
PBS, pH 7.2. Scale bar = 100 nm. 
In human papillomavirus (HPV) VLPs, the presence of urea is reported to decrease the 
rate of assembly. This can be implied to explain the observation that during Aerosil 
elution, a low VLP count is observed despite the presence of significant concentration 
of HBsAg in lysate, as indicated by the gel densitometry (Figure 4.10). 
There have been reports stating the effects of several environmental factors such as 
pH, Ca
+
 ion and ionic strength on the assembly process of other VLPs [103]. The 
presence of bivalent cation has been claimed to be important in the in vitro assembly 
process. Studies have shown that calcium ion is required for the particle stabilization 
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[76]. Other studies have shown that in the case of HPV, Zn
+2
 influences the assembly 
negatively because of its involvement in aggregation [104].  
The effect of pH on the fact that no VLP assemblage is observable in initial steps 
cannot be ruled out. It has been reported that the pH plays an important part in the in 
vitro formation of VLPs [78, 103]. It is shown that the Norwalk VLPs, for example, 
can withstand appropriately acidic pH but in alkaline condition (pH 8.0), the 
dissociation occurs [105]. However in the present study, the pH appears to be least 
decisive. During the lysis and PEG precipitation, the pH is kept at 8.0 whereas during 
Aerosil binding and washing it remains constant at pH 7.2. HBsAg is afterwards eluted 
from Aerosil using buffer system with pH 10.8 and later stages exhibit pH condition 
similar to initial steps. As HBsAg contents are rather high in initial steps, we should be 
able to see VLPs accordingly. But since it is not the case here, it may lead to the 
conclusion that effects due to detergent and HCCs are more influential than that of pH, 
if at all, in case of HBsAg VLPs. 
The idea of denaturant-based solvent effect is indirectly supported by the in vitro 
assembly processes (of HBsAg as well as other VLP systems) where the subunits are 
produced and purified under the denaturing conditions. As soon as the purified product 
is added into the so called ‘assembly buffer’, the assembly process takes place 
resulting in the formation of VLPs. When the composition of ‘assembly buffer’ is 
closely inspected, it is simply a buffer with a particular ionic strength and suitable pH 
which allows subunits to acquire specific conformation [79, 104, 106]. Due to this 
switch in conformation, the subunits are spatially aligned with respect to each other so 
that they can bind together via their ‘active-sites’ [37]. 
Broadly speaking, the phenomenon of solvent influence on activity and conformation 
of proteins is not new. Since years, biologists have used certain salts and sugars as 
stabilizers to retain the activity of proteins. Concomitantly, the solvent constituents 
have also been manipulated to denature and renature the native protein structures. 
There are several principles involved in the stabilization of structure by solvent 
components. In short, the stabilization process can be considered as a reverse reaction 
of the defolding process, usually characterized by a two-state mechanism. In former 
case, the solvent additive tends to shift the equilibrium towards the native state, thus 
favoring the retention of native conformation and a stabilized system [107]. The effect 
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of solvent system on the VLP structure will be discussed in depth in the forthcoming 
pages. 
4.2.6. VLP count during the downstream process and control 
experiments 
The most obvious characteristic of HBsAg activity is the VLP formation itself. In 
order to scrutinize the influence of various factors quantitatively, the VLP count was 
determined during the routine downstream process as well as the control experiments 
(Figure 4.17). For control experiments, VLP count from control-4 (purified VLPs in 
PBS, pH 7.2) was considered as reference to calculate the percent VLP count. The 
samples in control experiments contain the same amount of HBsAg as in respective 
samples from routine downstream processing. 
It can be observed that VLP appear for the first time during Aerosil elution step. The 
absence of VLPs before this step, despite the presence of high amount of HBsAg in the 
lysate, can be explained on the expense of rigorous buffer systems and HCCs. Further 
quantitative analysis of the HBsAg VLP count during the control experiments provides 
a deeper understanding into the effects of milieu factors, i.e. HCCs and buffer system, 
on the VLP assembly. In this analysis, the VLP count in control-4 i.e., purified VLPs 
in PBS, pH 7.2 is considered as a reference with which the rest of the results are 
compared to. 
 




Figure 4.17. Quantitative survey of the VLP formation during routine and control 
experiments. The upper most panel (A) shows % VLP count (w.r.t. total HBsAg contents) 
of the samples during routine HBsAg purification process. The initial four steps were 
further investigated in the control experiments. Control-1 is the purification process of P. 
pastoris GS115 whereas in control-2, VLPs were added in their corresponding samples 
from control-1. Control-3 comprises purified VLPs in the buffer systems pertaining to the 
initial purification steps and control-4 contains VLPs in PBS, pH 7.2 as a reference. 
Middle left panel (B) represents the VLP count of P. pastoris GS115 lysate samples from 
the four control experiments whereas middle right panel (C) is for the second step i.e. 
PEG precipitation. Lower left (D) and right (E) panels show results from the Aerosil 
binding and elution steps, respectively. For each measurement, on average, 4-5 images 
were used and the counting was done via ImageJ. 
The VLP count during the routine downstream processing suggests that VLP appear 
for the first time during the Aerosil elution step. At this step, only 7% of the total 
HBsAg is assembled into the VLPs (Figure 4.17, panel A). The similar trend is 
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observed during ion exchange chromatography. A 15-fold increase in the VLP count is 
observed at GF step i.e., from GF load to GF eluate. At this point, the HBsAg purity 
increases to almost 2-fold due to the removal of HCPs (Figure 4.11, panel A). This 
increase in the VLP count at this step is 13 fold higher than the increase in purity of 
HBsAg.  
The 15-fold increase in the VLP count during GF can be explained on the expense of a 
favorable buffer system (PBS, pH 7.2), apart from the removal of host cell proteins. A 
further theoretical explanation can be presented by the assumption that VLPs are being 
formed on-column. This may be supported by the fact that the VLP assembly is 
promoted by the presence of relatively higher purity of the subunit protein i.e. HBsAg. 
Moreover, the presence of an optimal buffer system helps to expedite the assembly 
process.  
It is observed that the VLP count decreases by 95% during their incubation in the 
samples comprising P. pastoris GS115 cell lysates (Figure 4.17, panel B). During the 
control experiment, investigating the PEG precipitation step, a decrease of about 10% 
was observed in control-2 and -3 samples. However during the later steps, Aerosil 
binding and elution, the loss decreases to 30-80 percent. This trend suggests that 
together the host cell contents and the purification buffer system have influence on the 
in vitro VLP assembly. 
It can also be comprehended that the solvent system (control-3) has a stronger effect 
on the VLP dissociation as compared to the HCCs as the VLP number decreases to 
almost 5 percent after addition of VLPs in purification buffer for the lysis and the PEG 
precipitation. Nonetheless, the impact of HCCs cannot be ruled out altogether because 
the last two samples in control-2, i.e. Aerosil binding and elution, express 30 percent 
decrease in the VLP number whereas the solvent system does not contain very strong 
constituents like Tween 20 or EDTA. This decrease may be well explained by the 
presence of HCPs to a concentration of around 40% of the total protein contents in the 
sample (Figure 4.11). 
4.2.7. Effect of Tween 20 and EDTA on VLPs 
It has been observed from the previous experiments that VLPs do not appear suddenly 
en masse. The formation of VLPs is a gradual procedure which occurs step by step. 
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The first step to observe VLPs in the purification process is after the Aerosil elution. 
Results from the  routine purification during initial two steps i.e. lysis and PEG 
precipitation do not show any particles whereas control experiment-2 and -3 suggest 
that the samples from these steps exhibit a decline in the count of purified VLP when 
added afterwards.  
The above observation could be explained on the account of buffer composition during 
these purification steps which provide a hostile environment for the VLP structure. 
When these buffer systems are carefully scrutinized, there are two possible 
components which may be responsible for the instability of VLPs, namely Tween 20 
and EDTA. Tween 20 is a nonionic polyoxyethylene surfactant used to facilitate the 
lysis and release of the protein from cellular compartments [108]. It has a critical 
micelle concentration (CMC) of 0.0074% (w/v) or 0.06 mM. EDTA, a polyamino 
carboxylic acid, is a chelating agent. It is used in the lysis buffer commonly to serve 
two purposes. Firstly, it chelates Ca
+2
 ions involved in the intercellular and intra-
cellular adhesion (in lipid bilayer) to get a better break down of the cells. Secondly, it 
inhibits the divalent cations which are co-factors of certain enzymes involved in the 
degradation of proteins and DNA.  
In order to verify conclusively the effect of Tween 20 and EDTA, the lysis was 
performed in absence of each constituent one by one. Control lysate-1 (CL-1) contains 
the routine lysis buffer. CL-2 and CL-3 are lysates in the absence of Tween 20 and 
EDTA, separately, whereas the CL-4 lacks both components, together. The typical 
lysate in lysis buffer [25 mM sodium phosphate buffer, pH 8, 5 mM EDTA, 0.6 % 
(v/v) Tween 20] is shown in the figure 4.18.  
 




Figure 4.18.  A survey view of the HBsAg producing P. pastoris cell lysate (CL-1) via 
TEM. Here the total protein concentration is 0.5 mg/mL. Scale bar = 1000 nm.  
In general, cell lysates with Tween 20 are more homogenously stained (e.g., 
figure 4.18). TEM survey indicates that in the sample with regular lysis buffer as well 
as without Tween, no intact VLPs are present. However some random VLP 
agglomerates in the form of well-packed clusters can be observed. The size of each 
particle in this cluster corresponds to an HBsAg VLP. Overall a significant amount of 
agglomerated structures are observed in all lysate samples, however their characteristic 
appearance varies.  
 




Figure 4.19. An example of VLP agglomerate present in the cell lysate. These VLP 
clusters were seen in the samples without Tween 20 (CL-2). The inset A shows close up 
of this agglomerate. Notice that the size of particle is similar to that of a mature intact 
VLP. In the inset B, an aggregate from P. pastoris GS115 cell lysate is shown (scale 
bar = 50 nm), for comparison purpose. The difference of this aggregate from VLP 
agglomerate can be well observed due to its random morphology. Scale bar (main 
image) = 1000 nm.  
Due to its detergent properties, Tween 20 decreases the surface tension and renders the 
samples homogeneity. Therefore, most of the agglomerated VLP patches are observed 
in the samples lacking Tween 20. These densely-packed proteinaceous structures are 
easily distinguishable because of their thick stain. Due to their spatial geometry they 
soak more stain, because of the capillary effect, and hence appear darker in color. For 
better examination of such structures, the image intensity (and magnification) was 
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In order to better comprehend the role of Tween 20, it is important to explain its 
mechanism of interaction with the proteins. Usually, the non-ionic surfactants can be 
used to increase the stability of stored proteins. There are many physical factors 
involved in the protein aggregation and a common believe to trigger the aggregation is 
the adsorption of hydrophobic regions of protein on the interfaces e.g. vessel and 
interfacial surfaces. Surfactants like Tween 20 may inhibit the aggregation process by 
binding to the hydrophobic regions, however their capacity is quite limited [109, 110]. 
Tween 20 has also been claimed to influence the release of HBsAg from the cellular 
compartments [111]. In this study, it was observed that Tween 20 disrupts the striated 
HBsAg membranes (Figure 4.23) by decreasing hydrophobic interaction and this may 
possibly help in the release of protein from ER. 
More interesting structures were found in the lysate samples CL-3 and CL-4 (Figure 
4.20, 4.21). In samples lacking EDTA, lamellar structures with definite membrane 
pattern were observed. Due to their thick stain, they are clearly distinguishable from 
rest of the structures. On first sight, they appear as a local aggregate of sample due to 
staining procedure. When observed closely, with adjusted brightness and contrast 
settings, they are found as stacks of membranous layers lying over each other. These 
stacks of lamellar membrane exhibit characteristic thickness as well as interlayer 
distance (Figure 4.20, 4.21). 
 




Figure 4.20. A close up of agglomerated protein patches in the lysate sample in absence 
of EDTA. The striated lamellar structure of HBsAg can be seen in close-up insets. In 
close-up B, few random VLPs are present on the edges of the aggregate. Scale bar for 
main image = 1000 nm, for image A and B = 200 nm 
The structures found in the samples without EDTA resemble to those found in the 
endoplasmic reticulum (ER) of HBsAg-producing P. pastoris cells. This observation 
can be attributed to the chelating effect of EDTA. Being a chelating agent, EDTA 




) which are responsible for the 
membrane stability. It has been reported previously that EDTA helps to release the 
proteins bound to the cellular membranes in yeasts [112]. In Gram-negative bacteria, 
EDTA has been found to enhance the effect of antibiotics by destabilizing the cell 
walls [113]. This is done by chelating the bivalent ions in the outer membrane of 




Electron microscopic analysis 
62 
 
In the absence of EDTA, these structures retained their integrity, including the ER 
membrane where HBsAg accumulates. The fact that HBsAg remains localized in the 
ER has been used artfully by Kee et al. as exploitation of cellular compartments for the 
ease in purification process [115]. 
 
Figure 4.21. Striated lamella in lysate sample in the absence of EDTA (CL-3) with 
regular pattern (A). The similar membranous structures have been observed in the ER of 
HBsAg-producing P. pastoris cells (B- adapted from Lünsdorf et al. [75]). 
Scale bar = 100 nm. 
In CL-3 (sample without EDTA), the thickness of a lamellar layers and the distance 
between them was measured via iTEM software. The average thickness of one single 
layer was found to be 6.38 nm (SD = 0.97 nm) whereas the interlayer distance was 
4.2 nm (SD = 0.24 nm). The lamellar structures were sought also in lysate samples 
with regular lysis buffer as well as lysis buffer without Tween 20. The typical striated 
pattern could not be found as such, however on close examination, the agglomerates 













Figure 4.22. Close up of the agglomerated protein stacks in samples with lysis buffer 
(CL-1). These structures are distinctively different from those found in the absence of 
EDTA as the typical lamellar pattern is missing here. Scale bar for main image = 10 µm; 
for close-ups = 200 nm. 
In samples with EDTA, instead of lamellar membranes, the disrupted agglomerates of 
proteins were found (Figure 4.22). As mentioned earlier, EDTA helps to disrupt the 
cellular membranes by binding to the bivalent cations. In samples lacking EDTA, 
HBsAg remains attached to ER membrane, and as a result lamellar structures are 
observed (CL-3 and CL-4). In samples with EDTA, HBsAg is released from ER 
membrane but, due to the presence of Tween 20 and HCCs in the solution, forms 
disrupted lamellar membranes (Figure 4.22, panel A, B and C). These structures have 









Figure 4.23. Single VLPs and VLP agglomerate in the sample CL-4 (cell lysate in 
phosphate buffer, pH 8.0). Scale bar = 200 nm for image A; 100 nm for image B 
In sample without Tween 20 and EDTA, some single VLPs could be observed 
(Figure 4.23 A). The number of single VLPs is not very high as compared to the 
purified sample with same HBsAg contents. Moreover, the compactness of these VLPs 
is not well-defined and they do not seem to contain the typical octahedral geometry. 
This may be explained on the account of deterring effect of some host cell components 
on VLP assembly.  







CL-1 Lysis buffer no no no yes 
CL-2 Lysis buffer without Tween 20 no yes no yes 
CL-3 Lysis buffer without EDTA no no yes no 
CL-4 
Lysis buffer without Tween 20 
and EDTA 
Yes* yes yes no 
Table 4.3. Summary of structures observed in the TEM analysis of samples examined for 
the effect of Tween 20 and EDTA (control-5) 
* not seen very often (as compared to sample containing pure VLPs) 
On the basis of above results, it may be inferred that the absence of VLPs in lysate 
during routine downstream processing is due to the influence of Tween 20 and EDTA. 
In the absence of both, HBsAg is present in form of striated lamellas (as present in ER 
of P. pastoris cells [75]) or clusters of closely-packed VLPs. However this cannot be 
A B
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misinterpreted as an evidence for a stable particulate structure as the morphology of 
VLPs in these samples is not so well-defined when compared to the purified product. 
4.2.8. Conclusion 
In this study, the factors affecting the self-assembly of HBsAg VLPs during the 
downstream processing were identified. As standard, samples from the routine 
downstream process were examined via TEM. For background structure, GS115 cell 
lysate was treated in the same way as routine purification method, and the samples 
were collected from this process (control-1). These samples were introduced with 
purified HBsAg VLPs for 24 h at 4°C (control-2). The experiments pertaining to 
incubation of the purified VLPs in purification buffers (Table 4.2) and storage buffer 
(PBS, pH 7.2) were named as control-3 and control-4, respectively. Lysis test in 
various combination of the lysis buffer components were called control-5. 
On the basis of micrographs from routine downstream process, it could be concluded 
that the VLPs start appearing after treatment with Aerosil 380 (fumed Silica), increase 
in number during the ion exchange chromatography and the tendency towards the 
formation of single and well-defined VLPs (from clump formation) enhances 
significantly after size exclusion chromatography where the non-VLP HBsAg (e.g., 
aggregated form) is removed. The partial defolding-refolding with KSCN helps to 
polish the loose ends in VLPs. It has been already established that KSCN treatment 
helps to increase the cross-linking due to disulfide bonds in HBsAg particles [86]. This 
gradual development of VLP quality is also illustrated by the trend from clump 
formation, in the beginning of downstream process, to the individual VLPs at the end. 
In general, the impurities decrease and the VLP count increase concurrently during the 
course of purification.  
It was observed during control-2 experiment that VLPs lost their define structure as 
well as integrity when added to initial steps of downstream process. Hence it was 
deduced from the control purification experiments that the environmental factors play 
very crucial role in the VLP assembly as well as morphology. Two central factors were 
deduced to be HCCs and solvent system. 
The later control experiments in presence of P. pastoris proteins and purification 
buffer systems (control-2 and -3) indicated that the morphology of VLPs is disturbed 
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and their number decreases, irrespective of presence or absence of HCP. Hence, it was 
concluded that components from host cell may not be as crucial as the buffer system. 
However, quantitatively, this effect is still influenced by the HCCs. 
During the downstream processing, the morphology of VLPs improves gradually as 
well as the VLP count. It has been noted that the tendency of VLPs to stick together 
decreases over the whole process and later stages exhibit more stable and compact 
particles with more uniformity in shape and size. 
The absence of VLPs in initial steps of purification is conceived to be partially due to 
the presence of Tween 20 and EDTA, in addition to the HCCs. In order to examine the 
effect of buffer system, the control experiment containing the constituents of lysis 
buffer in different combination was performed. The control lysis in the presence and 
absence of Tween 20 and EDTA, individually and together, gave a very useful insight 
into the VLP assembly during downstream processing. In samples with Tween 20 and 
EDTA (CL-1), no intact VLPs could be observed. The Patches of protein with distinct 
lamellar membranes are observed in the absence of EDTA where the membranes from 
yeast cells are not disrupted and HBsAg, due to its hydrophobic nature, remains 
associated with the remnant membrane of ER. In the presence of EDTA i.e. in CL-1 
and CL-2 the distorted structures are observed, which are possibly the HBsAg lamella, 
disfigured by Tween 20 and HCCs. The clusters of agglomerated VLPs are observed in 
CL-2 and CL-4 i.e., only in the absence of Tween 20 as due of the detergent effect of 
Tween, these structures may get dissolved in the lysate solution  
In the light of the above stated results, it can be stated that during assembly process, 
HCCs as well as denaturant-containing buffer play pivotal roles. The gradual removal 
of adverse buffer system and HCCs results in the occurrence of self-assembled HBsAg 
VLPs. 
According to the present study, the decisive factor in the in vitro assembly of HBsAg 
VLP during the downstream process is chiefly the presence of components like 
Tween 20, EDTA and urea in the buffer system whereas the HCCs also seem to play a 
deterring role in this respect. 
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4.3. Monitoring of conformational changes in HBsAg VLPs 
in the presence of chaotropic agents via steady-state 
fluorescence spectroscopy 
In previous section, the probing of downstream process of HBsAg via TEM was 
discussed. The assembly of HBsAg VLPs during the purification process was 
examined comprehensively and the factors involved in it were studied. Here, it is a 
matter of special interest to analyze the stability of VLPs via defolding studies. The 
defolding series serve double purpose; first, as the name suggests, they give an idea 
about the stability of VLP. Secondly, they help to better understand the assembly 
process, as the defolding is a reverse process of self-assembly. Therefore, in this part 
of work, purified HBsAg VLPs were put under the denaturing conditions and the 
changes occurring as a result of this were observed via fluorescence spectroscopy. 
Later the fluorescence spectroscopic observations were verified by other parallel 
techniques such as by virus counter which works on principle of flow cytometry and 
by dynamic light scattering measurements.  
Fluorescence spectroscopy is one of the most accurate and handy optical techniques to 
investigate the structure of proteins. In the last two decades, a large number of 
applications involving fluorescence, steady-state as well as time-resolved, have 
emerged in discipline of biochemistry and biophysics. Being non-destructive it has an 
advantage over many other analytical techniques which render the sample unfit for 
further use.  
The intrinsic fluorescence properties of a protein arise from the aromatic residues, 
tryptophan, tyrosine and phenylalanine [116]. This is mainly because of the indole 
ring, specifically determined by the electrical potential difference across the long axis 
of the indole ring [117]. On the other hand, extrinsic properties are rendered by the 
fluorescent probes. Most of the probes bind covalently to different amino acids in a 
protein, e.g. via the ɛ-amino group of lysine, the α-amino group of the N-terminus, or 
the thiol group of cystein. Some fluorescent dyes attach noncovalently to the protein 
degradation products, e.g. via hydrophobic or electrostatic interactions [118]. In this 
study, both extrinsic and intrinsic fluorescent measurements were carried out to 
observe the effect of chaotropic reagents.  
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4.3.1. Fluorescence spectroscopic studies of HBsAg VLPs 
In general, fluorescence properties of proteins can be used to observe the product 
formation online as well as offline. Moreover, fluorescence spectroscopy makes it 
possible to have a close look into the protein structure at molecular level because 
fluorescence properties are influenced by the local electrostatic environment. In this 
study, conformational changes of the HBsAg, after treating with chaotropic salts, were 
observed via steady state fluorescence spectroscopy.  
4.3.1.1. HBsAg intrinsic fluorescence measurements 
As mentioned previously, one HBsAg subunit comprises 226 amino acids. The 
fluorescence excitation spectrum shows maxima at 320 nm, which indicates that most 
of the intrinsic fluorescence is by virtue of its tryptophan residues while a small part 
comes from the tyrosine residues. This is in compliance with the previous reports [83, 
119]. 




Table 4.4. Important amino acid residues in one subunit of HBsAg w.r.t. intrinsic 
fluorescence properties 
4.3.1.2. Extrinsic fluorescence measurements  
Fluorescent dyes are excellent tools for monitoring the change in microenvironment of 
proteins in solution. In general, the phenomenon of protein fluorescence on account of 
an extrinsic dye may occur via either of two main mechanisms. The first mechanism 
involves a shift of charge, as a result of excitation, in dye molecule and consequently 
in the solvent around it. This creates fluorescence on account of more suitable 
conformation of the molecule. The second mechanism involves exchange of electron/s 
leading to the intramolecular charge transfer (ICT) [120]. 
There are many probes available for the characterization of lipoproteins, most famous 
of them being ANS (8-anilino-1-naphthalenesulfonic acid) and bis-ANS (4,4′-
Dianilino-1,1′-binaphthyl-5,5′-disulfonic acid). Bis-ANS is sensitive to change in the 
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environment with respect to polarity and viscosity hence giving idea about 
hydrophobicity of the protein. The binding equilibrium between protein and bis-ANS 
gives valuable information about the protein structure [118].  
In present work, bis-ANS was used to monitor the structural changes in HBsAg 
induced by denaturants. The structural formula of bis-ANS is given in figure 4.24.  
 
Figure 4.24. Structural formula of Bis-ANS, the fluorescent dye used for binding with the 
hydrophobic domains 
Ostensibly bis-ANS binds with the protein on account of hydrophobic as well as ionic 
interactions. The major binding force between the protein and bis-ANS is reported to 
be hydrophobic interactions. However, the electrostatic interaction between anionic 
sulfonate groups from the dye and cationic amino acids also help to make the protein-
dye complex [121]. Its monomeric form, ANS, is used to quantify the surface 
hydrophobicity of proteins [122]. 
The parameters for fluorescence measurements of HBsAg are summarized in table 4.5. 
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4.3.2. Denaturation studies of HBsAg 
In the field of biochemistry, unfolding studies in presence of denaturants has provided 
useful insight into protein conformation. The transition from native to unfolded state 
and reverse can occur via two-state kinetic or folding intermediates [123-125]. Either 
way, the equilibrium between folded and non-folded protein alters in the presence of 
denaturant. The ease (or difficulty) with which a protein undergoes these transitions is 
used to interpret its structural stability [126]. In general, both increase and decrease in 
fluorescence intensities can occur during the denaturation experiments. 
In this experiment, the changes in fluorescence prosperities of HBsAg VLPs were 
studied by performing the denaturing experiments with different chaotropic agents. 
Chaotrope is a reagent which disrupts the structure of a macromolecule [127] and 
hence increases the entropy. Chaotropic reagents have the ability to interfere with 
hydrogen bonding and van der Waals forces in a substance. Denaturing (chaotropic) 
reagents induce quenching effect which can be used to measure the accessibility of 
fluorophores and hence indirectly the conformational changes in proteins. Such studies 
in VLP technology help to explain structural aspects as well as, indirectly, mechanism 
involved in cell entry and viral replication [128]. 
The chaotropes opted for this study are, GdnSCN, KSCN and GdnHCl. GdnSCN is a 
commonly used denaturant with, both anion and cation, as strong chaotropes. 
Similarly, GdnHCl is widely used to follow the unfolding curve of proteins [129]. It is 
known that unfolding induced by GdnHCl and urea mostly leads to randomly coiled 
conformation [130]. The main reason for using KSCN is that it is used in partial 
defolding step during downstream process of HBsAg. The purpose of using multiple 
denaturants is to understand the structure of VLPs from multiple prospects. 
In this study, some preliminary tests were performed to see the scope of change in the 
fluorescence profile, intrinsic as well as extrinsic, under native and denatured 
conditions. The initial results indicate an obvious difference between fluorescence 








Figure 4.25. The emission spectra of HBsAg VLPs in native and denatured form (after 
treating with 6 M GdnSCN). Black and grey spectra correspond to intrinsic fluorescent 
properties of native and denatured forms of HBsAg VLPs. The extrinsic fluorescence 
profile is shown in dark and light green colored spectra for native and denatured VLPs 
respectively. The signals near the base belong to buffer in absence (blue) and presence 
(pink) of fluorescent dye.  
This preliminary data indicates that intensity maximum exhibits a small red shift from 
about 340 nm to 350 nm. This shift in the emission maximum is because of change in 
vicinity of tryptophan residues. In later studies it was observed that throughout a 
transition curve, under the influence of all chaotropic salts used, the maxima showed a 
linear increase, from 340 nm to 350 nm i.e. a shift of 10 nm.  
 
Figure 4.26. The Red shift in fluorescence maxima in the presence of chaotropic agent. In 
this case, 2 µM HBsAg was treated with GdnSCN (0 – 6 M) and the trend in fluorescence 
maxima was observed.  
The initial experiments showed that the effect of denaturant salts on the defolding 
curve was almost the same when the VLPs were incubated for 3 min or 24 h at 25°C 
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(Figure 4.27). The incubation after 48 h resulted in a linear trend showing no change in 
the fluorescence intensity between samples with and without GdnSCN. This may be 
because of loss of the VLP structure due to incubation at 25°C. 
 
Figure 4.27. The trend in defolding curve of HBsAg VLP in the presence of GdnSCN. 
The sample containing 2 µM HBsAg VLP were incubated with GdnSCN (0 – 6 M) at 
25°C. The incubation time is 3 min (panel A), 24 h (panel B) and 48 h (panel C). 
The transition curves under the effect of denaturants are represented in the figure 4.28. 
As it can be seen, the intrinsic fluorescence profile does not contain any drastic change 
in the transition curve. On the contrary, a meager and steep curve is observed in 
presence of GdnSCN and KSCN. GdnHCl does not show any significant change in 
intrinsic fluorescence intensity which appear to be due to inaccessibility of non-
covalent interactions and/or disulfide bonds of VLP. It is known that solubilizing 
ability of GdnHCl is more leaned towards nonpolar groups, which are buried in the 
inner core of VLPs [130, 131].  
The general modest profile of intrinsic fluorescence properties of HBsAg VLPs can be 
arguably supported by “molten globules” as folding intermediates. The partially folded 
conformation of protein, so called molten globule, is formed under mild denaturing 
conditions and is different from native protein by the fact that it does not contain the 
tertiary structure as do the native proteins [132, 133]. However these molten globular 
proteins are markedly stable under a wide range of environmental conditions such as 
acidic change, presence of denaturant etc [134]. Based on this fact, it may be deduced 
that VLPs, during initial stage of transition curve, acquire molten globular 
conformation which explains the observation that VLPs do not show a significant 
change in their intrinsic fluorescence properties. However, when bound to fluorescent 
dye, the change in micro environment becomes rather obvious.  
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As discussed earlier, no significant change was observed in the intrinsic fluorescence 
of HBsAg particles during chaotropic transition curves. However the extrinsic 
fluorescence data, in presence of bis-ANS, shows interesting results. Bis-ANS is an 
example of solvent relaxing probes used to characterize the micro viscosities and 
polarities of protein solutions. Interestingly, it is reported to hinder the viral assembly 
when bound to the dimer. The speculated reason for it is that bis-ANS binds to dimer 
interface which is a very suitable location for a molecular wedge [135].  
 
Figure 4.28. Denaturing curves of the HBsAg VLPs during treatment with chaotropic 
agents. The panels A, B and C on left hand side represent the intrinsic fluorescence curves 
in presence of GdnSCN, KSCN and GdnHCl respectively. Similarly panels D, E and F on 
the right hand side show changes in the extrinsic fluorescence after treating with same 
chaotropic agents. Bis-ANS (4,4′-Dianilino-1,1′-binaphthyl-5,5′-disulfonic acid), a dye 
which is sensitive to change in environment with respect to polarity and viscosity was 
used as the fluorescence probe. 
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No typical two-state unfolding kinetics could be observed, irrespective of sort of 
chaotrope used. A two-state kinetic is representative of unfolding of globular proteins, 
with which VLPs are frequently compared to. However this comparison is irrational 
due to the reason that VLP is an entity comprising of several subunits, unlike a 
globular protein. The inter-molecular interaction is, therefore, of prime importance in 
this structure. 
During the extrinsic studies, transition trend with both GdnSCN and GdnHCl showed a 
peculiar curve, although with peak position at different concentration of the chaotrope 
salt. In transition curve, the initial thrust in extrinsic fluorescence is attributed to the 
formation of a molten globule-resembling partially folded form, which possesses a 
quasi-native structure (Figure 4.29). Due to loose structure, the molten-globular 
structure has increased solvent-exposed hydrophobic surface area as compared to the 
native state. This is why even the buried hydrophobic cavities become exposed to the 
solvent and a substantial increase in intensity is observed. On further increase of 
denaturant concentration, the secondary and tertiary structure is disturbed which leads 
to the loss of hydrophobic cavities and consequently a decrease in the fluorescence 
intensity (Figure 4.28).  
 
Figure 4.29. Supposed mechanism of the defolding process monitored via fluorescence 
measurements in the presence of bis-ANS. An initial increase in the (extrinsic) 
fluorescence intensity is due to access of more hydrophobic regions to the fluorescence 
dye, which suggests the presence of a quasi-molten globular structure in the defolding 
curve. 
The fluorescence data shows that GdnSCN exposed the hydrophobic cavities around 
0.5 M salt concentration. This has been suggested in a previous study by Zhao et al. as 
well [119]. In the presence of GdnHCl, this point is shifted to around 1.2 M. The 
specificity of GdnHCl for polar groups is higher than that for non-polar groups which 
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explains that GdnHCl is weaker chaotrope as compared to GdnSCN. A similar trend 
has been observed in the unfolding studies of papain in presence of GdnHCl [136]. 
The denaturation with KSCN did not show similar curve which can be explained by 
the fact that KSCN is a chaotropic reagent which also acts as destaining agent [137]. 
Apparently it dissociates the protein-dye complex which produces the fluorescent 
signal. Therefore the extrinsic fluorescence measurements are not as evident as in 
presence of other chaotropic agents. 
4.3.3. Stern-Volmer relation 
Stern-volmer equation is a very useful relation to analyze the condition of residues of a 
protein in a certain milieu [138]. 
F° / F = 1 + KSV [Q] 
Above equation was used to measure the stern-volmer plot of VLPs in presence of 
GdnSCN, KSCN and GdnHCl (Figure 4.30).  
 
Figure 4.30. Stern-Volmer plot of HBsAg VLPs under the quenching effect of GdnSCN 
(A), KSCN (B) and GdnHCl (C). 
The stern-Volmer plots reveal an exponential curve under the denaturing effect of 
KSCN, which suggests that the fluorescence is dominated by a single amino acid 
residue. The GdnSCN and GdnHCl plots show a linear trend which indicates that the 
residues display different degree of exposure to the denaturant and thus are not equally 
accessible. This behavior is because of the fact that tryptophan residues, which 
constitute the major source of fluorescence, are present in different environmental 
arrangement [139]. Keeping in view the VLP structure, it is implied that the HBsAg 
VLPs comprise of hydrophilic and hydrophobic regions in distinctive conformation. 
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The model of a lipoprotein with hydrophobic inner core surrounded by a compact lipid 
monolayer has been already suggested in Hansenula polymorpha-derived HBsAg [82]. 
4.3.4. HBsAg VP count determination using Virus counter 
The results from denaturation studies were further ascertained by the measurements via 
Virus counter (ViroCyt 2100, InDevR Inc. USA). In this case, due to their more 
obvious transition in intrinsic fluorescence curve, GdnSCN and KSCN were selected 
to verify the results obtained from fluorescence measurements (Figure 4.28). Here the 
virus particle count (VP count) is estimated by the combined data of protein and 
nucleic acid signals. An example of PMT signal for a VLP sample is shown in 
figure 4.31. 
 
Figure 4.31. A Raw data screenshot of the VP count of purified HBsAg particles. The 
peak area is close up of only a part of one single measurement. Notice that the protein and 
nucleic acid signals appear simultaneously. 
The results from GdnSCN defolding, represented in the figure 4.32, correlate to the 
fluorescence profile of HBsAg in presence of series of GdnSCN. Since it was observed 
that the obvious changes occurred at a concentration of 0-3 M, the measurements via 
ViroCyt were performed in presence of chaotrope within this range of GdnSCN 
molarity. The tendency of total VP count implies that increasing molarity of GdnSCN 
leads to gradual decline of intact particles. The initial increase of protein contents may 
be attributed to the exposure of residues in milder unfolding conditions which leads to 
a succeeding decrease due to the stronger denaturation effect. 
 




Figure 4.32. HBsAg VP count during the GdnSCN treatment. The upper box corresponds 
to total VP number ascertained via virus counter by combining the protein and nucleic 
acid quantitative results. The middle and lower box represents these results individually. 
The samples with KSCN denaturation could not be measured due to its destaining 
effect. Thiocyanate ions in KSCN have dissociative property and therefore may have 
disturbed the protein-dye complex [137]. This results in the breaking of bonds between 
hydrophobic amino acid residues and dye molecule which ultimately results in no 
fluorescence signal, as fluorescence dye alone exhibits no fluorescence.  
The instrument, by default, measures not only the collective VP count but also the 
protein- and nucleic acid contents individually. In case of HBsAg VLPs, the 
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with protein signal, it was considered that it does not belong to free nucleic acid 
present in the sample as contaminant. One plausible explanation which can be inferred 
in this case is that the dye (provided in kit from instrument’s manufacturer) binds 
nonspecifically with the lipid contents of VLP and hence generates a synchronized 
signal. Second speculation is that this signal is observed due to the host cell genetic 
material trapped inside the HBsAg VLPs during the process of downstream. The 
encapsulation of host cell contents during self-assembly is a common problem 
encountered during VLP downstream processing [140, 141]. Since the contents of so-
called Combo dye are confidential, it could not be ascertained that what the origin of 
nucleic acid PMT signal is. 
4.3.5. Dynamic light scattering measurements 
Light scattering provides information about the molecular mass and size of a protein in 
solution. It can nicely distinguish between the native and non-native biomolecules. In 
order to monitor the size of VLPs as a function of chaotropic molarity, experiments 
were carried out via dynamic light scattering (DLS) technique. Since the purpose was 
to confirm the trend observed in intrinsic fluorescence results, the conditions for the 
sample preparation were kept similar as those for the fluorescence studies. 
4.3.5.1. Preliminary DLS studies 
To begin with, HBsAg was treated with 6M of all three chaotropic salts and compared 
with native VLP scattering results. The initial results with DLS showed a similar trend 
in transition curve as that observed via intrinsic fluorescence. The gradual decrease in 
structural integrity and lack of a typical two-state mechanism are unanimously visible 
by both techniques. The VLP size by DLS measurement i.e. 12 nm (data not shown) 
was observed to be not in agreement with the TEM data. It was assumed that the 
discrepancy in size occurs because of a population in the solution other than VLP.  
4.3.5.2. Discrepancy in VLP size via DLS 
Since the production of VLP is a biosynthetic process, the presence of small molecular 
weight (SMW) species and aggregates cannot be rule out altogether. In principle, VLP 
self-assembly and aggregation exist simultaneously and in competition with each other 
[77]. Moreover storage of even a pure product in sterile conditions can still lead to the 
aggregation. Originally, it was not clear that whether this difference of size is because 
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of SMW species, mono-, di-, tri-, oligomer etc, or it is caused by the aggregates. In 
order to figure out these reasons, the sample was analyzed via electron microscopy. 
The TEM images showed the presence of a miner amount of aggregates, in addition to 
the VLPs still being the dominant population (data not shown).  
4.3.5.3. Effect of SMW species 
As TEM has arguably a size limitation of ~2 nm (depending on the staining 
procedure), it was not possible to verify the presence of monomer which has a 
theoretical size of 2.4 nm. The sample was filtered via spin column of cut-off size 300 
kDa to remove the SMW species present, if any. The DLS measurements were 
repeated using the same protocol. Since no change in the trend and VLP size was 
observed (Figure 4.33), the presence of (substantial amount of) of SMW species was 
ruled out. As a cross-check, the filtrate from the spin column was analyzed via DLS as 
well as SDS-PAGE. No significant amount of HBsAg or any other protein was 
observed in this fraction. The collective results of former experiment are shown in the 
figure 4.33. 
 
Figure 4.33. Histograms of the DLS measurements of native HBsAg VLPs (A) as well as 
in the presence of GdnSCN (B), KSCN (B) and GdnHCl (D). Note that in presence of 
denaturant, the size (diameter) has been shifted towards the left hand side of histogram. 
The results are presented in terms of scattering caused by the percentage mass.  
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It can be observed from the graph that the diameter of the VLPs is still smaller than the 
observed (as well as reported) diameter via EM techniques. Whereas, in case of 
HBsAg VLPs, it has been seen that diameter observed via DLS is bigger than that via 
TEM. The reason for this is probable dehydration of sample while the sample 
preparation [142].  
4.3.5.4. Effect of aggregates 
It has been proposed that the yeast-derived HBsAg in crude extract is highly prone to 
aggregation [143]. This is particularly because of the synthesis method of VLPs. The 
steps which involve concentration or removal of salts are usually performed via ultra 
filtration. Due to the protein-protein and protein-surface interactions during these 
steps, HBsAg tends to form aggregates. These aggregates still may retain the 
antigenicity; however during the aging the activity reduces to about 20 % [89, 102].  
During DLS analysis of the sample devoid of SMW, the VLP size still does not 
coincide with the EM (as well as reported) data. DLS data indicates the presence of 
high molecular weight (HMW) specie (size ranging from 200 nm to 250 nm). The 
occurrence of this HMW specie is rather rare as compared to VLPs i.e. 1:20,000-
30,000. The discrepancy in VLP size due to aggregation has been reported earlier by 
Kee et al. [108] 
It is known that the presence of large aggregates causes strong scattering which 
presumably surpass the scattering caused by 22 nm particles. In DLS, the signal 
intensity is dominated by the size which may be the reason that the large size aggregate 
over-scatter the signal of smaller particles. This may mislead to the representation of 
size distribution, especially in case of a sample consisting of multiple populations. The 
variance in the HBsAg VLP size observed by DLS has been reported earlier by Kee et 
al. [108].  
4.3.5.5. Optimized DLS measurement 
DLS is a very convenient and useful technique but it provides more reliable and 
accurate results for samples consisting of a narrow size-distribution. Considering the 
previous observations, the purified product was filtered via a viva spin column of cut 
off 300 kDa to remove SMW species. Subsequently, this protein solution was filtered 
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via a membrane of cut-off 0.2 µm to remove large size aggregates. DLS measurements 
were carried out according to the previously described protocol. The graph in 
figure 4.34 represents the observations found in optimized DLS evaluation. The 
fluorescence results from denaturation series are represented in figure 4.28.  
 
Figure 4.34. The effect of chaotropic salt on the VLP size (diameter) monitored via DLS. 
Three chaotropes were used for this study i.e., guanidine thiocyanate (panel A), potassium 
thiocyanate (panel B) and guanidine hydrochloride (panel C). The trend in each case is 
shown by a curve fitting. 
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In case of all three denaturants, a gradual decrease in the VLP size was observed. It 
can be seen that the curve here coincides with trend observed in the intrinsic 
fluorescence profile of HBsAg VLPs. Also here, no two-state mechanism could be 
observed. A hypothetical mechanism of defolding process, based on the denaturation 
curves, is presented in the figure 4.35. 
 
Figure 4.35. A pictorial explanation of the defolding process of VLPs in increasing 
concentration of denaturant. As a result of the defolding effect, the VLPs assume molten 
globular structure. As the concentration of denaturant increases, the subunits start to 
dismantle gradually, ultimately leading to denatured HBsAg subunits. 
The general mechanism seems to be the gradual disruption of VLP structure, plausibly 
with several intermediates. Based on the intrinsic fluorescence data and above DLS 
measurements, it is suggested that under denaturing conditions, VLPs lose their 
structure slowly yet steadily. This may happen as a gradual detachment of subunits 
which results in complete disassembly of VLP and ultimately ends up in the presence 
of only randomly coiled structures. 
4.3.6. Conclusion 
Several spectral approaches were applied to monitor the structure of HBsAg VLPs. 
Initial fluorescence measurements suggest the dominance of tryptophan emission with 
less contributing signal from tyrosine residues. Time-resolved fluorescence 
spectroscopy measurements were used to calculate the Stern-Volmer relation. The 
Stern-Volmer plot connotes that most of fluorescing residues are present in 
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heterogeneous environment which is supported by the VLPs lipoprotein model in 
which phospholipids constitute a hydrophobic core and HBsAg subunit proteins are 
immersed in it.  
The structural stability of VLPs was studied by adding a gradually increasing series of 
chaotrope. In this study three different chaotrope salts were used, namely GdnSCN, 
KSCN and GdnHCl. The changes in conformation and structure were observed via 
steady-state fluorescence microscopy. It was observed that the intrinsic fluorescence 
decrease gradually during the course of denaturing series with GdnSCN and KSCN. 
However, there was no evident change observed while treating with GdnHCl. Intrinsic 
properties did not show any considerable change during the treatment with GdnHCl. 
However, KSCN and GdnSCN transition curve showed a meager yet steady decrease 
in the fluorescence intensity.  
In case of HBsAg VLPs, while treating with chaotropic reagents, no typical two-state 
unfolding curves were observed. A gradual decrease in intrinsic profile of fluorescence 
intensity suggests that the unfolding of HBsAg VLPs takes place via folding 
intermediate. On the basis of initial increase and further decrease in extrinsic 
fluorescence properties, it is suggested that a molten globular structure exists as 
folding intermediate. 
The changes in VLP size during the denaturation curve were ascertained via DLS 
measurements as well. The data indicates a gradual decrease in the diameter, unlike a 
two-state mechanism as observed in most globular proteins. In this respect, DLS 
results verify the trend noticed in the intrinsic fluorescence properties of VLPs. It can 
be concluded that due to their distinctive structure, VLPs undergo denaturation process 
by several intermediates, which occur as a cascade of reactions involving gradual 
detachment of subunits. This is suggested on the basis of gradual decrease of VLP size 
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5. Summary and perspectives 
Worldwide millions of people die and many more suffer from side effects of one or 
other disease. There is an old but still equally valid saying, “prevention is better than 
cure”. Vaccines play a major role in prevention of many illnesses every year. The 
concept of vaccination buds from 18
th
 century by Edward Jenner whereafter it 
extended vastly. In traditional medication against a viral disease, mostly attenuated or 
inactivated vaccines have been used in the previous decade. In the last two to three 
decades, VLP vaccines have been in focus due to their better efficacy and safety 
aspects. VLP technology makes use of a particle which mimics the actual virus 
structurally, but lacks chiefly the genetic material. Therefore, VLP vaccines are much 
safer as well as equally effective. However, the self-assembly of VLPs has been a 
poorly discovered area. 
It has been known that in bacterial and yeast-based systems, the VLPs do not occur 
inside the cell, which leads to the proposition that they may be formed during the 
purification process. In the work presented in this thesis, an effort has been made to 
figure out the stage(s) where VLP are formed during the downstream processing. Later 
the factors affecting the self-assembly have been scrutinized and structure-based 
stability studies have been scrutinized. Here HBsAg VLPs have been used as a model 
system. 
The successful production and purification of HBsAg VLPs has been reported in this 
thesis. HBsAg was produced in P. pastoris GS115 cells with 8-copy cassette in a 10-L 
bioreactor using basal defined media. The cells were grown in batch mode with 
glycerol as sole carbon source. After the complete consumption of glycerol, methanol 
feed was started in fed-batch mode. The cultivation was harvested 136 h after 
induction at OD600=330. During the cultivation, HBsAg production was confirmed by 
the Western blot and ELISA. 
Multi-step downstream processing was applied to obtain the purified HBsAg. Cells 
were lysed using high-pressure homogenizer to release the intracellular contents. The 
lysate was subjected to PEG precipitation and the supernatant was proceeded with 
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adsorption on fumed silica (Aerosil® 380). The Aerosil eluate (supernatant) was 
bound on anionic exchange resin and the fractions containing HBsAg were pooled. 
The pooled HBsAg fraction was further purified by using size exclusion 
chromatography, to obtain only VLPs and remove non-VLP HBsAg. The main peak in 
20% void volume indicates that large part consists of VLPs with a tailing consisting of 
non-VLP HBsAg as well as remaining HCPs. The fractions pertaining to VLPs were 
pooled and treated with KSCN to a final molarity of 1.2 M. The VLPs were dialyzed 
against PBS, pH 7.2 to remove the KSCN. The final product was examined via TEM 
to confirm the assembly of VLPs.  
It is observed that a large amount of HBsAg is lost during the initial steps of 
purification, particularly, during PEG precipitation and adsorption and elution from the 
Aerosil. Further optimization is required to decrease the loss during these stages. It is 
recommended that PEG precipitation should be further optimized using various NaCl 
and PEG concentration to reduce the product loss. It might be interesting to try 
different sizes of PEG to get better recovery. Moreover different media for 
hydrophobic interactions should be tried out in order to achieve a higher yield of 
HBsAg. 
Since the downstream process ensures formation of VLPs reproducibly, further step 
was to probe thoroughly the purification protocol. Samples were collected during 
purification procedure and analyzed via TEM. The TEM analysis showed that VLPs 
appear for the first time after the Aerosil elution (treatment based on hydrophobic 
interaction forces) and the morphology and the number improves drastically after the 
size exclusion chromatography where the non-VLP HBsAg is removed. A 12-fold 
increase in VLP count is observed from ion exchange chromatography to the gel 
filtration. The gradual development of VLP quality is also illustrated from the trend of 
clump formation to the individual VLPs at the end of downstream process. In general, 
the impurities decrease and the VLP count increase concurrently during the course of 
purification. 
In order to pin point the crucial factors, several control experiments were performed in 
the presence and absence of purification buffers and HCCs. On the basis of 
quantitative examination of VLP morphology and count during these control 
experiments, it was concluded that although HBsAg in present in the lysate, the 
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rigorous buffer system and HCPs impede the self-assembly process. Moreover, the 
VLPs are dissociated more drastically in sample containing lysis buffer and crude 
lysate. 
The lysis buffer contains two peculiar constituents i.e. Tween 20 and EDTA. The TEM 
control experiments with different combination of these both constituents show that 
Tween 20 and EDTA disturb the HBsAg arrangement existing in host cell ER. In 
absence of Tween 20 (CL-2), the clusters of agglomerated VLPs are frequently 
observed in the cell lysate. Moreover, some random distorted lamella are also seen 
which, due to their partially stacked structure, appear to be remnants of HBsAg 
lamella. It may be concluded that Tween 20, due to its detergent effect, helps to 
dissolve the agglomerates and therefore in its absence, these lamellar structures are 
present in the lysate. 
It has been reported in the literature that HBsAg is present in form of striated lamellas 
intracellularly [75]. The TEM data indicates that in absence of EDTA, the typical 
HBsAg lamellas exist frequently in the lysate. EDTA, being a chelating agent, binds to 
the divalent cations stabilizing the ER membrane and helps in the release of HBsAg. 
However in the absence of EDTA, these lamellar structures retain their arrangement. 
The striated lamellar structures are not found in samples CL-1 and CL-2, i.e. in 
presence of EDTA. It may lead to the conclusion that Tween 20 as well as HCCs 
disrupt the lamellar arrangement.  
Tween 20 or EDTA alone are not the decisive factors and hinder the assembly 
simultaneously. Additionally, the HCCs also execute negative effect on VLP 
assembly. However, further studies would be required to ascertain the specific effect of 
P. pastoris HCCs. It might be of interest to analyze the HBsAg VLPs in presence of 
certain groups of P. pastoris homologous proteins and enzymes to further ascertain the 
HCC effect. Moreover the production of HBsAg in other expression system and its 
comparison with HBsAg-producing P. pastoris lysate can provide advance insight.  
The structural aspect of VLPs and their stability was monitored via defolding curves 
using GdnSCN, KSCN and GdnHCl. The changes were monitored via steady-state 
fluorescence spectroscopy. The intrinsic properties indicated that VLPs lack a two-
state mechanism in defolding process. It was concluded that a quasi-molten-globule 
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structure exists as intermediate in VLP transition curve. The extrinsic fluorescence 
profile in presence of hydrophobic dye shows an initial increase and then decrease of 
intensity. This trend corresponds to first exposure of hydrophobic cavities to the dye 
and subsequent disruption thereof, as a function of chaotrope concentration. This 
transition trend was verified also via DLS measurements.  
The DLS data affirms the absence of two-state kinetics which is quite plausible, 
keeping in view the intrinsic fluorescence data besides the characteristic structure of a 
VLP. It may be concluded that VLPs dissociate gradually in increasing molarity of 
denaturant till the whole structure is distorted. The size of HBsAg VLP via DLS shows 
as discrepancy of 8-10 nm. It has been proposed that presence of aggregated form 
leads to stronger scattering as compared to that caused by VLP which leads to an 
imprecise particle size. It is strongly recommended that further studies using 
multiangle light scattering (MALS) with field flow-filed fractionation (AF4) should be 
carried out. This system works on a similar principle as that of SEC except that the 
separation of different sized species is more accurate. The individual specie fractions 
should be monitored for defolding studies to obtain more authentic curve, devoid of 
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Abbreviation  Augmentation 
A. niger   Aspegillus niger 
BCA    Bicinchoninic acid 
Bis-ANS 4,4'-Dianilino-1,1'-Binaphthyl-5,5'-Disulfonic Acid, 
dipotassium Salt 
BMG    Buffered minimum glycerol 
BMGY   Buffered glycerol-complex medium 
BMM    Buffered minimal methanol 
BMMY   Buffered methanol-complex medium 
cccDNA   covalently-closed circular DNA 
CHO cells   Chinese hamster ovary cells 
DCs    Dendritic cells 
DEAE    Diethylethanolamine 
DLS    Dynamic light scattering 
DM    Defined media 
DO    Dissolved oxygen 
E. coli    Escherichia coli 
EDTA    Ethylenediaminetetraacetic acid 
ELISA    Enzyme-linked immunosorbent assay 
ER    Endoplasmic reticulum 
FPLC    Fast protein liquid chromatography 
GdnHCl   Guanidine hydrochloride 
GdnSCN   Guanidine thiocynate 
GF    Gel filtration 
HBcAg   Hepatitis B core antigen 
HBsAg   Hepatitis B surface antigen 
HBV    Hepatitis B virus 
HCC    Host cell component 
HCP    Host cell protein 







    Histidine (requiring auxotroph) 
HMW    High molecular weight 
IEX    Ion exchange chromatography 
IgM    Immunoglobulin M 
KDa    Kilo dalton 
KSCN    Potassium thiocynate 
LHBs    Large Hepatitis B protein 
MeOH    Methanol 
MHBs    Middle Hepatitis B protein 
Mut
+
    Methanol utilization plus (phenotype) 
Mut
S
    Methanol utilization slow (phenotype) 
MWCO   Molecular weight cut off 
OD    Optical density 
P. pastoris   Pichia pastoris 
PB    Phosphate buffer 
PBS    Phosphate buffered saline 
PEG    Polyethylene glycol 
RP-HPLC   Reverse phase-high performance liquid chromatography 
rpm    Revolutions per minute 
RT    Room temperature 
SDS-PAGE Sodium dodecyl sulfate polyacrylamide gel 
electrophoresis 
SEC    Size exclusion chromatography 
SEM    Scanning electron microscopy 
Semi-DM   Semi defined medium 
SMW    Small molecular weight 
TEM    Transmission electron microscopy 
VLP    virus-like particle 
VP    Viral particle 
WHO    World health organization 
YNB    Yeast nitrogen base 






Chemicals    Manufacturer 
All common lab reagents used were purchased Sigma-Aldrich unless stated otherwise. 
Here only some specific reagents are mentioned.  
Histidine    Sigma-Aldrich Chemie GmbH, Germany 
TEGO® Antifoam KS911  Evonik Industries AG, Germany 
Tween 20 (for synthesis)  Merck Schuchardt OHD, Germany 
EDTA (disodium salt)  Sigma-Aldrich Chemie GmbH, Germany 
Bis-ANS    Sigma-Aldrich Chemie GmbH, Germany 
Guanidine thiocyanate  Sigma-Aldrich Chemie GmbH, Germany 
Guanidine hydrochloride  Sigma-Aldrich Chemie GmbH, Germany 
Potassium thiocyanate  Carl Roth GmbH, Germany 
YNB, without amino acids   BD Difco, MD USA 
and ammonium sulfate 
Reagents    Manufacturer 
PageRuler (unstained) SM0661 Fermentas 
PageRuler (prestained) SM0671 Fermentas 
NovagenYeastBuster
TM
 Protein  Merck KGa, Darmstadt, Germany 
extraction reagent 
Pierce BCA protein Assay kit  Thermo Fisher Scientific 
AP conjugate substrate kit  Bio-rad, München, Germany 
HBsAg ELISA kit   bioMérieux, France 
Antibodies    Manufacturer 
Goat anti-mouse polyclonal   Acris antibodies GmbH, Germany 
FPLC resin    Manufacture 
Aerosil ® 380    Evonik Degussa GmbH, Rheinfelden, Germany 
DEAE Sepharose FF    Amersham Pharmacia Biotech, Sweden 
HiPrep 26/60 Sephacryl S-300  GE healthcare 
High Resolution 
Equipments   Manufacturer 






Autoclave    Systec V-150, Systec GmbH Wettenberg 
Incubator (Shaker) Certomat ® BS-1, B.Braun Biotech International 
Bioreactor    Biostat C, B.Braun Biotech International 
Gas analyzer Modular System, S710, SICK MAIHAK GmbH, 
Reute 
Centrifuge Centrifuge Stratos, Continuous flow rotors, 
Heraeus 
Centrifuge Megafuge, Heraeus Instruments 
Cell lyser Microfluidizer M110L, Microfluidics, Newton, 
MA 
Light microscope   Axiopot, Carl Zeiss AG, Oberkochen 
Gel electrophoresis system  Mini Protean Tetra Cell, Bio-rad, München 
Spectrophotometer    Cary, Multiskan Spectrum, Thermo Labsystems 
(Absorbance measurement) 
HPLC     Merch-Hitachi La Chrome, Darmstadt 
FPLC BioLogic Duo-Flow, Bio-Rad, München 
Luminescence spectrometer   Hitachi 
Luminescence spectrometer   PerkinElmer Ltd., United Kingdom 
Virus counter    ViroCyt 2100, InDevR Inc. USA 
Dynamic light scattering  DynaPro Titan, Wyatt Technology Corporation 
Software    Manufacturer 
RISP software Institute of technical chemistry, University of  
(Bioreactor on-line data collection)  Hannover 
BioLogic DuoFlowV.5 Bio-Rad Laboratories, Inc.   
(FPLC)    
OriginPro 8    OriginLab Corporation, MA    
ImageJ U.S. National Institutes of Health, Bethseda, MD 
(TEM Image processing)      
Graphic Analyzer  Institute of Technical Chemistry, University of  
(TEM Image processing) Hannover   
CRISP ver. 2.1   Calidris, Sollentuna, Sweden 





FL WinLab Software   PerkinElmer Ltd., United Kingdom 
 (Fluorescence analysis)    
Dynamics Version 6.10  Wyatt Technology Corporation 
(DLS measurements) 
Nucleotide and amino acid sequence of the PCR amplified HBsAg 
gene 
 
GAATTCAAGCTTGGATAAAAGA ATG GAG AAC ATC ACA TCA GGA TTC CTA GGA CCC CTG 51 
        Met Glu Asn Ile Thr Ser Gly Phe Leu Gly Pro Leu 12 
 
CTC GTG TTA CAG GCG GGG TTT TTC TTG TTG ACA AGA ATC CTC ACA ATA 99 
Leu Val Leu Gln Ala Gly Phe Phe Leu Leu Thr Arg Ile Leu Thr Ile 28 
 
CCG CAG AGT CTA GAC TCG TGG TGG GCT TCT CTC AAT TTT CTA GGG GGA 147 
Pro Gln Ser Leu Asp Ser Trp Trp Ala Ser Leu Asn Phe Leu Gly Gly 44 
 
TCA CCC GTG TGT CTT GGC CAA AAT TCG CAG TCC CCA ACC TCC AAT CAC 195 
Ser Pro Val Cys Leu Gly Gln Asn Ser Gln Ser Pro Thr Ser Asn His 60 
 
TCA CCA ACC TCC TGT CCT CCA ATT TGT CCT GGT TAT CGC TGG ATG TGT 243 
Ser Pro Thr Ser Cys Pro Pro Ile Cys Pro Gly Tyr Arg Trp Met Cys 76 
 
CTG CGG CGT TTT ATC ATA TTC CTC TTC ATC CTG CTG CTA TGC CTC ATC 291 
Leu Arg Arg Phe Ile Ile Phe Leu Phe Ile Leu Leu Leu Cys Leu Ile 92 
 
TTC TTA TTG GTT CTT CTG GAT TAT CAA GGT ATG TTG CCC GTT TGT TCT 339 
Phe Leu Leu Val Leu Leu Asp Tyr Gln Gly Met Leu Pro Val Cys Ser 108 
 
CTA ATT CCA GGA TCA ACA ACA ACC AGT ACG GGA CCA TGC AAA ACC TGC 387 
Leu Ile Pro Gly Ser Thr Thr Thr Ser Thr Gly Pro Cys Lys Thr Cys 124 
 
ACG ACT CCT GCT CAA GGC AAC TCT ATG TTT CCC TCA TGT TGC TGT ACA 435 
Thr Thr Pro Ala Gln Gly Asn Ser Met Phe Pro Ser Cys Cys Cys Thr 140 
 
AAA CCT ACG GAT GGA AAT TGC ACC TGT ATT CCC ATC CCA TCG TCC TGG 483 
Lys Pro Thr Asp Gly Asn Cys Thr Cys Ile Pro Ile Pro Ser Ser Trp 156 
 
GCT TTC GCA AAA TAC CTA TGG GAG TGG GCC TCA GTC CGT TTC TCT TGG 531 
Ala Phe Ala Lys Tyr Leu Trp Glu Trp Ala Ser Val Arg Phe Ser Trp 172 
 
CTC AGT TTA CTA GTG CCA TTT GTT CAG TGG TTC GTA GGG CTT TCC CCC 579 
Leu Ser Leu Leu Val Pro Phe Val Gln Trp Phe Val Gly Leu Ser Pro 188 
 
ACT GTT TGG CTT TCA GCT ATA TGG ATG ATG TGG TAT TGG GGG CCA AGT 627 
Thr Val Trp Leu Ser Ala Ile Trp Met Met Trp Tyr Trp Gly Pro Ser 204 
 
CTG TAC AGC ATC GTG AGT CCC TTT ATA CCG CTG TTA CCA ATT TTC TTT 675 
Leu Tyr Ser Ile Val Ser Pro Phe Ile Pro Leu Leu Pro Ile Phe Phe 220 
 
TGT CTC TGG GTA TAC ATT TAA TAGG TCGACAAGCTTGAATTC   724 
Cys Leu Trp Val Tyr Ile      226 
 
 
The HBsAg gene was PCR amplified from hepatitis B virus DNA (subtype adw) using 
primers containing Eco RI site to facilitate subsequent cloning of the gene into Pichia 
expression vectors. The start (in blue) and stop (in red) codons are italicized. The 












































Glycerol (g/l) 10  10  95.2 60 60 60 
*Methanol 
(% volume per 
litre) 




13.6 13.6 13.6 13.6 9.4 9.4 4.3 4.3 
YNB  
(% w/v) 
1.34 1.34 1.34 1.34     
Biotin  
(mg/L) 
0.4 0.4 0.4 0.4 0.4  0.4  0.4   
Yeast extract 
(g/L) 
  10 10     
Peptone 
(g/L) 
  20 20     
**Histidine 
(g/L) 
0.04 0.04 0.04 0.04 0.04 0.04 0.04 0.04 
Casein 
hydrolysate (g/l) 
      10 10 
(NH4)2SO4 
(g/L) 
    15.7 15.7 15.7 9 
KH2PO4 
(g/L) 





































    1.83 1.83 4.6 3.2 
CaCl2.2H2O 
(g/L) 
    0.28 0.28 0.28 0.22 
CaSO4.2H2O 
(g/L) 
        
YTM soln 
(g/L) 
    1.14 1.14 4.56  
PTM 1 
(mL/L) 
       5 
 
* MeOH was used in after-induction phase. 
** Histidine was added for the growth of his4 strains only. 
 
Recipe of Media for bioreactor cultivation 
 
Component Amount in 1L Amount in 9L Make the vol. up to Sterilization 
Glycerin [99.5%] 105.71 g 951.39 g n.a. Autoclave 
KH2PO4 10.28 g 92.52 g 771.30 g w/ H2O 
(≈750 mL H2O) 
Autoclave 
(NH4)2SO4 17.14 g 154.26 g 771.30 g w/ H2O 
(≈750 mL H2O) 
Autoclave 





CaCl2. 2H2O 0.309 g 2.78 g 771.30 g w/ H2O 
(≈750 mL H2O) 
Autoclave 
Biotin 0.45 mg 4.1 mg 20.55 g w/ H2O Filter sterilize 
Anti-foam  100 g  Autoclave 
NH3-H2O  512.30 g n.a.  
MeOH   n.a. Filter sterilize 
YTM   n.a. Filter sterilize 
 
Yeast trace metal solution (YTM) 
 
Component For 1000 g For 100 g 
KI 207.50 mg 20.75 mg 
MnSO4.H2O 760.59 mg 76.059 mg 
Na2MoO4 483.9 mg 48.39 mg 
H3BO3 46.37 mg 4.637 mg 
ZnSO4.7H2O 5031.95 mg 503.195 mg 
FeCl3.6H2O 12.03 mg 1.203 mg 
H2SO4 [98 %] 9.20 mg 0.920 mg 
 









Buffers for HBsAg downstream process 
Step Buffer  pH 
lysis 25 mM PB, 8.0 + 5 mM EDTA  
+ 0.6% Tween 20 
8.0 
PEGylation / PEG precipitation 
(O/N) 
lysis buffer + 500 mM NaCl  
+ 5% PEG 6000 
8.0 
Aerosil binding 25 mM PB + 500 mM NaCl 7.2 
Aerosil washing 25 mM PB   7.2 
Aerosil elution 50 mM CBB + 1.2 M Urea 10.8 
Aging 50 mM CBB   10.8 
IEX binding 50 mM CBB   8.0 
IEX washing 50 mM Tris-HCl 8.0 
IEX elution Tris-HCl + 500 mM NaCl 8.0 
Concentration via vivaspin 
column 
50 mM Tris-HCl  
+ 500 mM NaCl 
8.0 
SEC  PBS, 7.2 7.2 
KSCN PBS, 7.2 + 1.2 M KSCN 7.2 
Dialysis PBS, 7.2 7.2 
PB: (Sodium) phosphate buffer 
CCB: Sodium carbonate-bicarbonate buffer 
PBS: Phosphate buffered saline 
Phosphate buffered saline, pH 7.2  
Compoundt Concentration [M] Concentration [g/L] 1X Concentration [g/L]10X 
NaCl 137  8.00 80.0 
KCl 2.7 0.20 2.0 
Na2HPO4 10.0 1.44 14.4 
KH2PO4 1.76 0.24 2.4 
pH 7.2 7.2 7.2 
Dissolve all the salts in ddH2O and mix together. Adjust the pH with conc.HCL or 





Glycerol stock Glycerol stock was used as pre Pre-culture for shake flask and 
bioreactor cultivations of HBsAg producing and non-producing 
clones. In order to prepare glycerol stock, pick an isolated single 
colony of HBsAg producing Pichia pastoris GS115 cells and 
grow in YPD till OD600=12-14. Resuspend in YPD containing 
15% glycerol to obtain a final OD600=50-52 (≈2.6 10
9
 
cells/mL). Aliquot and shock freeze in liquid N2. Store at −80°C. 
Aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa 
OD600nm  Throughout the cultivations (in shake flasks as well as 
Measurement  bioreactor), cell optical density (OD) was measured via 
spectrophotometer. At different stages during cultivation, time 
point samples were collected and OD was measured at 600nm. 
The instrument was calibrated for zero-adjustment with 0.9% 
(w/v) saline solution before all the measurements. Wherever 
necessary, dilutions were made with calibration solution. The 
dilutions were made, in a proportion of 1:5, 1:10, 1:20, 1:50 etc, 
in order to obtain the observed absorbance value in a range of 
0.1 – 0.8. 
Aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa 
Cell lysis 
Cell Lysis using  Wash cell pellet with 25 mM PB, pH 8.0 and resuspend in  
glass beads  lysis buffer. Add glass beads [0.45 mm; Sigma G-8772] of 
roughly equal weight to cell pellet. Vortex for 40 sec at 
maximum speed and keep at ice for next 40 sec. Repeat the 
cycle of vortexing and chilling 8-10 times. Centrifuge for 
10 min at 13,000 rpm (17,000 × g). Collect the supernatant and 
store at −20°C. (−80°C for longer term) 
Cell lysis via  Resuspend the cell pellet in lysis buffer and pass through the  
Microfluidizer Microfluidizer. During this process, the cells are pushed through 
the interaction chamber at high pressure, and passed through a 
cooling coil. Tighten the screws on the pressure compartment of 





the air supply, open valve to create pressure (5-8 bar). Add 100 
mL water; slowly turn on the red handle counter clock wise. Let 
it run for some passages to get isopropanol out. Repeat the water 
wash. Wash once with 20 mL lysis buffer. Pass cells at 12,000 
psi (38 psi at inlet) through Microfluidizer for 12-14 times. 
Confirm the complete lysis by viewing the sample under 
microscope. 
After lysis, wash out with buffer until it runs clear. Wash with 
100 mL 1 M NaOH and then with 500 mL water. Wash and fill 
with 70 % isopropanol for storage. 
Aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa 
SDS-PAGE recipe 
Following solutions are required for casting the gel, 
i. Acrylamid-bisacrylamid mixture, 37.5:1 
ii. 1.5 M Tris (pH 8.8) 
iii. 1.5 M Tris (pH 6.8) 
iv. 1% SDS solution  
v. Temed (N,N,N',N'Tetramethylethylenediamine) 
vi. 25 % APS (ammonium persulphate) 








1 Acryl-Bisacryl  
mixture 
3.0 mL Acryl-Bisacryl  
mixture 
0.75 mL 
2 Tris (pH 8.8) 2.5 mL Tris (pH 6.8) 1.25 mL 
3 SDS (1%) 1.0 mL SDS (1%) 0.52 mL 
4 dd H2O 1.76 mL dd H2O 2.46 mL 
5 Temed 20 µL Temed 10 µL 





SDS sample buffer 20 mM Tris-HCl 
   2 mM EDTA 
   5 % SDS (w/v) 
   0.02 % Bromophenol blue 
Modified Laemmli 50 % SDS sample buffer 
Sample buffer  45 % β-ME 
   5 % Glycerol 
Mix equal volume of Laemmli buffer and sample, boil at 95°C for 10 min and spin for 
1min to get all the contents down. 
Running buffer 25 mM Tris-Base 
 192 mM Glycin 
 0.1 % SDS (w/v) 
 pH 8.3  
Load the gel and run at 60 V for 15 min and at 120 V for 60 min (or until the end).  
Afterwards, stain the gel with colloidal coomassie or silver staining. 
____________________________________________________________________ 
Colloidal coomassie staining 
Reagents  a- For fixing solution 
       EtOH, 50%; O-H3PO4, 20% and ddH2O 30% 
b- For staining solution 
ddH2O, 270 mL; 85% O-H3PO4, 35.3 mL; (NH4)2SO4, 30g; 
Coomassie G-250, 0.36g; MeOH, 60 mL. 
Take 30 mL of ddH2O in a flask and add 30 mL H3PO4. Also 
add (NH4)2SO4 and Coomassie G-250. Shake and add the 
remaining 240 mL ddH2O. Lastly add MeOH slowly and 
dissolve using magnetic stirrer. 
Fixing After finishing the electrophoresis, rinse the gel briefly with 
ddH2O. To fix the gel, rinse it in the fixing solution for 2 times, 
20 min each.  
Staining Put the gel along with staining solution on the shaker and stain 
overnight. 
Destaining Rinse the gel with ddH2O until the background is clear and 





Storage This coomassie staining solution is reusable for nearly 6 months. 
Keep in amber bottle at 4°C. 
Silver staining 
Reagents  Fixing solution: 5 parts ddH2O, 5 parts EtOH and 1 part AcOH 
   (eg., 400 mL H2O + 400 mL EtOH + 80 mL AcOH) 
Farmer reducer: 0.1 g Potassium hexacyanoferrate (II) and 0.1g 
Sodium thiosulphate in 100 mL ddH2O 
0.1% AgNO3 solution: 1 small pinch in 100 mL ddH2O 
2.5 % Na2CO3 solution: 50 g Na2CO3 (dehydrated) in 1000 mL 
ddH2O 
Formaldehyde: 300-500 µL  per 100 mL Na2CO3 
Fixing and reduction Incubate the gel for 20 min in destaining/fixing solution. Wash 
quickly twice with ddH2O. Incubate in Farmer reducer solution 
for 2.5 min. Wash with ddH2O for 5 min. (wash till the yellow 
color is gone and the gel is again transparent) 
Staining Incubate in AgNO3 solution for 30 min. Wash for 30 sec with 
ddH2O twice. Wash swiftly with Na2CO3 solution. Add 400 µl 
formaldehyde in 100 mL Na2CO3 solution and incubate the gel 
in this solution until the bands are nicely visible. Stop the band 
development by adding the gel in 5% AcOH solution for 
10 min. Keep the gel in ddH2O. 
Aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa 
Western Blot 
Reagents Transfer Buffer: 25 mM Tris, 192 mM Glycin, 10% Ethanol, pH 
8.3 
1. TBS: 25 mM Tris, 150 mM NaCl, pH 7.5 
2. TBS-T: 25 mM Tris, 150 mM NaCl, 0.5% Tween 20, pH 7.5 
3. BSA-TBS (Blocking buffer): 25 mM Tris, 150 mM NaCl, 
0.5% Tween 20, 2% BSA, pH 7.5 
4. AP-Buffer: 100 mM Tris-HCl, 100 mM NaCl, 5 mM 
MgCl2.7H2O, pH 9.5 
5.  1° Ab Solution 





SDS-PAGE Run an SDS-PAGE using previously described conditions and at 
end, wash the gel with ddH2O. 
Preparation of  Cut the PVDF membrane of apt size and soak in MeOH/EtOH 
membrane for a minute or two and then immerse in ddH2O. Equilibrate the 
fibre pad, blotting paper, membrane and gel in transfer buffer 
for 15 min. Make the setup in the sequence such that it follows 
to make a sandwich as  fibre pad – blotting paper – gel – 
PVDF membrane – filter paper – fibre pad. Make sure to 
evacuate all trapped air bubbles underneath the gel with a roller. 
Place the sandwich fittingly onto cassette and close the clamp. 
Insert the cassette into blotter tank with red side facing red 
electrode.  
Fill up the blotter tank with transfer buffer till level n also put a 
magnetic stirrer and ice block. Put this tank in a tub filled with 
ice and onto a magnetic plate.  
Electro-transfer Put on lid, plug in the cables and start electro-blotting at a 
constant voltage for 30 min. At the end of the run, rinse the 
membrane with ddH2O for 5 min. Cross-check the gel for proper 
electrophoretic transfer (electroelution). 
Immunodetection Wash the membrane in ddH2O for 5 min.  Wash the membrane 
in BSA-TBS (blocking buffer) for 1 h. Incubate the membrane 
with 1° Ab solution for 1 h. Incubate the membrane with BSA-
TBS (3 X 5 min). Incubate the membrane with 2° Ab for 1hr. 
Wash 3 times with TBST (3 X 5min). Wash 2 times with TBS 
(2 X 1 min). Develop the signal by introducing membrane to the 
substrate solution. Stop the developing by adding ddH2O.  
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Protein estimation 
BCA Protein Assay 
For protein estimation via BCA assay, BSA is used as a standard protein. The 
concentration of stock solution is 2 mg/mL. Prepare a series of standard from stock 





Working Reagent  [WR]: Reagent A  +  Reagent B [50:1] 
                                                        3 mL  +  60 µL 
Sample + WR   [1:8 ratio]: 25 µL  +  200 µL  
(Microplate Procedure) 
Mix well and incubate for 30 min at 37°C. Read the plate at 562 nm. 
 
Absorption method Measure absorbance of the protein solution at 280 nm. Calculate 
the concentration by using the formula, 
Concentration = Absorbance at 280 nm / absorbance  
   coefficient*cell path length  
In all assays, the samples were diluted to appropriate concentrations to get results in 
the middle of assay range. 
Aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa 
HPLC protocol 
Column:   Supercosil LC-18 5 cm x 4.6 mm, 5 µm 
Detection:   UV 280 nm 
Solvent system:  A: 0.15% TFA in ddH2O; 
B: 2-propanol:ACN in 80:20 ratio 
Flow rate:  1 mL/min 
Time (min) A (%) B (%) C (%) 
0 55.0 45.0 0 
4 55.0 45.0 0 
10 5.0 95.0 0 
13 5.0 95.0 0 
14 55.0 45.0 0 
18 55.0 45.0 0 
 
TFA: Trifluoroacetic acid (Sigma-Aldrich Chemie GmbH, Germany 







FPLC protocol for Ion exchange chromatography* 
 Volume Description Parameters 
1 0.00 Collection Fractions within 2 time window(s) ending at 400.00 mL 
2 0.00 Lamp (UV Detector) Turn ON 
3 0.00 Zero Baseline  UV Detector 
4 0.00 Isocratic Flow A: A-Buffer 1 100% Volume: 100.00 mL 
B: Buffer B 0% Flow: 1.00 mL/min 
5 100.00 Isocratic Flow A: A-Buffer 2 100% Volume: 200.00 mL 
B: Buffer B 0% Flow: 1.00 mL/min 
6 300.00 Isocratic Flow A: A-Buffer 3 100% Volume: 100.00 mL 
B: Buffer B 0% Flow: 0.50 mL/min 
7 400.00 Lamp (UV Detector) Turn OFF 
 400.00 End of Protocol  
* The FPLC system (connected with column) was calibrated with first buffer system 
with at least 2 column volume (CV) before starting the run. All the buffers were 
filtered and degassed before use. 
 
 
Buffer 1: 50 mM Na-Carb-bicarb buffer   
Buffer 2: 50 mM Tris-HCl 








FPLC protocol for size exclusion chromatography* 
 Volume Description Parameters 
1 0.00 Collection Fractions of size 5.0 mL within 1 time window(s) ending at 
450.00 mL 
2 0.00 Lamp (UV Detector) Turn ON 
3 0.00 Zero Baseline  UV Detector 
4 0.00 Isocratic Flow A: A-Buffer 1 100% Volume: 50.00 mL 
B: Buffer B 0% Flow: 1.00 mL/min 
5 50.00 Isocratic Flow A: A-Buffer 2 100% Volume: 10.00 mL 
B: Buffer B 0% Flow: 1.00 mL/min 
6 60.00 Isocratic Flow A: A-Buffer 1 100% Volume: 360.00 mL 
B: Buffer B 0% Flow: 0.50 mL/min 
7 420.00 Lamp (UV Detector) Turn OFF 
 420.00 End of Protocol  
* The FPLC system (connected with column) was calibrated with first buffer system 
with at least 2 column volume (CV) before starting the run. All the buffers were 
filtered and degassed before use. 
 
 
Buffer 1: Ion exchange eluate 







Estimation of protein contents using ImageJ 
For SDS-PAGE densitometry 
1- Open ImageJ; drag and drop the image of gel. 
2-  Analyze  Gels  Select first lane [strg+1]. For next lane,  use [strg+2] n keep 
selecting until last desired lane. 
3- Once finished with selection,  Plot lane [strg+3]. 
4- Plot of image will pop up. Select the base line manually by drawing a horizontal 
line using ‘straight line’ selection tool. Draw vertical lines to define the peak/s. 
5- Before separating the peaks vertically, calculate the peak area by clicking inside 
using wand tool.  
6- Save the results separately for each lane; Results  File  Save as.  
7- Alternatively, label the peaks Analyze  Gels  label peaks. It gives peak area in 
percentage. 
For VLP count 
1- Open ImageJ; drag and drop the TEM image. 
2- Calibrate the pixels in terms of size by using the scale bar in the image (Analyze  
set scale). 
3- Select the circle option in the shape tool. 
4- Select all the VLPs as ROI (Analyze  tool  ROI manager). 







Step by step method of using Graphic Analyzer 
1- Open the image in Graphic Analyzer (A). 
2- Adjust Median Functions  Grey filters  Median[7-9] (B) 
3- Adjust threshold from grey filters [≈80-160] (C). 
4- Functions  Morphology  eliminate by size [≈600-3500] (D). 
5- Functions  Morphology  eliminate by compactness [1-2] (E) 
6- Get 8-connected objects (F) and save as CSV data. 
7- Get average of the diameter and convert into nm.  
E.g. if the scale bar ranges from 1582 to 2037 pixels, the difference 455 pixel equals 
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